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 Summary 
Natural products provide an important basis for the drug development in particular to 
fight the increasing resistance of microorganisms against existing drugs. Myxobacteria, 
gram negative ubiquitous soil bacteria belonging to the class of γ-proteobacteria, have 
proven an impressive capacity for the production of chemically intriguing natural 
products.  
In a chemical screening approach, Cystobacter fuscus MCy9118 was used to isolate new 
natural products based on chemical and structural features where two new compound 
families were identified and characterized. 
The cystomanamides are characterized by hydroxylated amino acids, an unusual 
branched chain fatty acid residue as well as N-glycosylation. The macyranones are 
unusual peptides belonging to the class of peptidic α’,β’-epoxyketones. Macyranone A 
exhibits potent and selective activity against Trypanosoma brucei rhodesiense, the parasitic 
agent causing the African sleeping sickness. The target was identified as 20S proteasome 
by enzymatic assays. A co-crystal structure of macyranone A with the yeast 20S 
proteasome revealed the binding mode underlying the compound-target interaction. 
Macyranone A represents the successful isolation of a new natural product with 
identified mode of action, which can be useful for the drug development process against 
the African sleeping sickness. 
The biosynthetic gene clusters for both compound families were identified as PKS / 
NRPS hybrids by in silico analysis and confirmed by gene deletion.  
 
  
 Zusammenfassung 
Naturstoffe bilden eine wichtige Grundlage zur Entwicklung neuer Wirkstoffe für die 
Arzneimitteltherapie, vor allem im Kampf gegen Antibiotikaresistenzen bei Pilzen, Viren, 
Parasiten und Bakterien. Myxobakterien, gramnegative ubiquitäre Bodenbakterien, haben 
eine beeindruckende Kapazität zur Produktion von chemisch faszinierenden Naturstoffen 
unter Beweis gestellt.  
Das Myxobakterium Cystobacter fuscus MCy9118 wurde in einem chemischen Screening 
auf die produzierten Naturstoffe hin untersucht und dabei konnten zwei neue 
Substanzfamilien charakterisiert werden.  
Die Cystomanamide weisen als besondere Strukturelemente hydroxylierte Aminosäuren, 
eine verzweigte Fettsäurekette sowie eine N-Glykosylierung auf. Bei der zweiten 
Substanzgruppe handelt es sich um die Macyranone, sehr ungewöhnliche Verbindungen 
aus der Gruppe der peptidischen α’,β’-Epoxyketone. Macyranone A zeigt biologische 
Aktivität gegen Trypanosoma brucei rhodesiense, dem parasitären Erreger der Afrikanischen 
Schlafkrankheit. Das 20S Proteasom konnte als Target identifiziert und durch eine 
Cokristallisation des Macyranone A mit dem 20S Proteasom der Hefe bestätigt werden. 
Damit konnte ein Naturstoff isoliert werden, der mit bekanntem Wirkmechanismus als 
Ansatzpunkt für die Entwicklung neuer Wirkstoffe gegen die Schlafkrankheit genutzt 
werden kann. 
Die Biosynthesegencluster beider Substanzklassen wurden durch in silico Analyse als 
PKS-NRPS Hybrid identifiziert und durch den Knockout von beteiligten Genen bestätigt.  
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1 Introduction  
1.1 Importance of Natural Products for Drug Discovery 
The idea of using natural biotic resources to treat a wide spectrum of bodily and mental 
defects goes back to the beginning of civilization. But only starting with the discovery of 
penicillin by Alexander Fleming in 1928,1 the concept of using natural products from 
microorganisms as starting material for the development of drugs has spread. Even if the 
number of pure natural products directly used as pharmaceuticals is comparatively small 
with 5% of the total amount of small molecule approved drugs between 1980 and 2010, 
the portion of natural product derived small molecules (34%) tells a different story. Also 
taking into account the compounds that are synthetically derived but simulate a natural 
product or its pharmacophore (30%) this adds up to 64% of the total number of 1073 small 
molecule approved drugs (Figure 1.1).2 These numbers impressively underline the 
importance of natural products for the drug discovery process.  
 
Figure 1.1: Source of small-molecule approved drugs (Figure modified from Newman & Cragg)1  
Natural products play a particular role in the fight against infectious diseases that 
comprise infections caused by bacteria, parasites, viruses and fungi. The increasing 
resistance against used drugs is a concern in all areas of application, as for example 
against antimalarial drugs as well as HIV drugs, but the rapidly emerging resistance to 
antibacterial drugs commonly used to treat infections are of explicit concern.3 Currently, 
few bacterial classes described as ESKAPE bugs (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and 
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Enterobacter species) cause the majority of US hospital infections and are able to “escape” 
the effects of antibacterial drugs.4 This development is compounded by the fact that, since 
the golden age of antibiotics in the 1970s, the number of new antibiotics in the drug 
discovery pipeline has dramatically decreased. Drug resistance is not only a big issue in 
the treatment of infectious diseases but also in the treatment of cancer. Multidrug 
resistance is a major factor in the failure of many forms of chemotherapy and it affects 
patients with a variety of blood cancers and solid tumors, including breast, ovarian, lung, 
and lower gastrointestinal tract cancers.5 How can natural products help to fight against 
the increasing drug resistance? The term natural product in principle refers to any organic 
material of biological origin but generally means a secondary metabolite. Secondary 
metabolites are small molecules with a molecular weight lower than around 1500 Da that 
are not essential for the survival, growth or development of an organism but they confer 
an evolutionary benefit to the producing organism.6 In contrast to chemically synthesized 
compounds, secondary metabolites are evolutionary designed to interact with a broad 
range of biological macromolecules and therefore we find a strong correlation from 
natural products to biological functionality together with a broad chemical diversity.6 
Natural products significantly enlarge the chemical space of synthetic libraries and they 
open the door for the development of new drugs as well as for the identification of new 
targets. 
1.2 Discovery of Natural Products from Myxobacteria 
Myxobacteria are Gram-negative δ-proteobacteria commonly found in soil samples. They 
are renowned for their social behavior and complex life cycle including the formation of 
colorful fruiting bodies under starving conditions as well as their micropredatory 
behavior.7 Their gliding motility facilitates colony growth and expansion, as well as 
behaviors such as chemotaxis, predation, and development.8 Besides this ability to move 
by gliding on solid surfaces, they are famous for their capability to produce a wide range 
of secondary metabolites.  
The ability of myxobacteria to produce antibiotic substances was already observed in 
19479 but systematic investigations concerning the secondary metabolites produced by 
myxobacteria have started with the formation of the Helmholtz Center for Infection 
Research in 1965 (Institute for Molecular Biology, Biochemistry and Biophysics (IMB) at 
that time). Since then, more than 100 natural product core structures and approximately 
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600 structural derivatives were reported in the literature.10 That the full potential is still to 
be realized is already proven by the fact that only our group published seven new 
compounds or compound families from myxobacteria in 2014, including the macrolide 
glycoside antibiotics disciformycin A and B,11 novel derivatives of the sponge metabolites 
microsclerodermins,12 the glycosylated lipopeptides cystomanamides,13 angiolactone14 
and hyafurones15, the siderophores hyalachelins16 and the cystobactamids17 adding up to 
a total of more than 160 new scaffolds from myxobacteria (unpublished results). 
Myxobacteria have proven an enormous potential for the production of secondary 
metabolites that exhibit mainly antifungal, antibacterial and cytotoxic activity as well as 
immunosuppressive, antiviral, antiplasmodial and antimalarial activity.18 This potential is 
of especial interest because myxobacterial compounds often target structures that are 
rarely hit by compounds from other producers. A novel mode of action bears the high 
chance to discover agents that circumvent resistance against existing drugs. A prominent 
example is the cytotoxic natural product epothilone that interacts with the eukaryotic 
cytoskeleton.19 It was isolated from the myxobacterium Sorangium cellulosum and the 
semi-synthetic analogue ixabepilone (Ixempra™) was approved 2007 for clinical use in 
the US for the treatment of aggressive breast cancer and can also be used to treat 
paclitaxel-resistant tumors.20  
The potential to produce such a chemical diversity is closely connected to the remarkable 
size of myxobacterial genomes. It was found that large genomes are enriched with 
secondary metabolite biosynthesis genes as well as genes involved in regulatory 
processes for secondary metabolite production. Konstantinos and Tiedje also found a 
correlation of the genome size and the habitat which made them conclude that 
“…bacteria with such [large] genomes are more ecologically successful in environments 
where resources are scarce but diverse and where there is little penalty for slow 
growth.”21 This is true for the soil habitat of myxobacteria and genome sizes that 
frequently comprise more than 10 Mbp and up to 14.8 Mbp from Sorangium cellulosum 
So0157-2.22 Even if little is known about the natural function of many secondary 
metabolites from myxobacteria, their “microbial rich” habitat as well as their 
micropredatory lifestyle could be reasons for their extraordinary capability to produce 
structurally diverse natural products. The species needs to protect its ecological niche in 
the highly competitive terrestrial environment.  
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Most of the myxobacterial secondary metabolites belong to the classes of polyketides 
(PK), nonribosomal peptides (NRP) or hybrids of both. They are biosynthesized by 
supersized multimodular assembly lines composed of polyketide synthase (PKS) and 
nonribosomal peptide synthetase (NRPS) multienzymes involving multistep biosynthetic 
processes. In general, these multienzymes are composed of domains where each domain 
carries out one biosynthetic step involving monomer selection and activation, binding of 
the substrates as thioesters, chain elongation and release. The domains are organized in 
functional modules and each module is typically responsible for the incorporation of one 
building block into the growing polyketide or peptide chain. The correlation between the 
enzyme architecture and secondary metabolite structure is known as the principle of 
colinearity. Simple building blocks such as dicarboxylic acids and amino acids are used to 
generate a wide range of complex natural products and the chemical diversity is 
expanded by enzymes introducing β-branching and post-PKS and NRPS reactions such as 
hydroxylation, glycosylation, and epimerization.23 The colinearity between the activities 
of modular domains and structure of the product allows the targeted manipulation of 
secondary metabolites by deletion, replacement or alteration of the single domains to 
study the biosynthesis or generate novel compounds.24–26  
The genes responsible for the biosynthesis of a secondary metabolite are usually located 
within a specific region of the bacterial chromosome, the so called biosynthetic gene 
cluster.27 Only this fact allows and simplifies the identification and investigation of 
complete secondary metabolite biosynthesis pathways because whole gene clusters can be 
identified by using signature genes.28 The arrangement of biosynthetic genes in clusters 
also allows the prediction of the products and vice versa, the chemical structure of a 
secondary metabolite gives an initial indication of the assembly of the biosynthetic gene 
cluster. Furthermore, the gene cluster structure of natural products biosynthesis genes 
enables the targeted manipulation of the secondary metabolites as well as its heterologous 
production in a convenient host. 
1.2.1 Polyketide synthases (PKS) 
Polyketides are an important class of natural products. Myxobacterial members of this 
diverse family of compounds are the already mentioned disciformycins11 as well as 
stigmatellin29, spirangien30, jerangolid31 and soraphen32 (see Figure 1.2). 
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Figure 1.2: Chemical structures of polyketides from myxobacteria. 
Looking at the structural diversity of polyketides, it is remarkable that they are the result 
of an assembly of some of the simplest biosynthetic building blocks: coenzyme-A (CoA)-
activated malonate or methylmalonate. PKSs show a high degree of similarity to FAS, 
both in the nature of the chemistry used in chain extension from simple precursors and in 
the character of the enzymes that are used for chain assembly.33 Research around fatty 
acid synthases (FAS) has greatly enhanced our understanding of polyketide synthase 
(PKS) mechanisms.34 The differences are caused by the higher flexibility of PKS in terms 
of choice of starter and extender units as well as the control of the reductive cycle (see 
below).35 PKS are divided into subgroups following the example set by FAS. Type I PKS 
are large multifunctional proteins each consisting of a series of catalytic domains. Type II 
PKS consist of discrete monofunctional enzymes with particular functions that mainly 
result in the biosynthesis of aromatic polyketides. The third type, the chalcone synthase 
type, consists of small homodimeric proteins.  
Type I PKS can be divided into two subgroups, the iterative PKS that is primarily found 
in fungi and the modular PKS that form giant multimodular megasynthases which are 
mainly found in prokaryotes.36 Polyketides can be seen as linear polymers where the 
polymer backbone consists of C2 units. During biosynthesis, every second carbon bears a 
ketone function, thus calling the compounds polyketides. The ketone groups can 
subsequently be processed via ketoreduction to hydroxy groups, via dehydration to the 
double bond and via enoyl reduction of the double bond to the fully reduced form.  
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Modular PKS pathways in homology to FAS pathways consist of several modules 
following the colinearity principle mentioned above. Each PKS module is responsible for 
the addition and manipulation of one polyketide subunit and the final number of ketide 
units in polyketides synthesized by regular type I (modular) PKS therefore equals the 
number of modules found in the PKS. Every module consists of several domains where 
each domain is responsible for one catalytic step. The action of three core domains – a 
keto synthase (KS) domain, an acyltransferase (AT) domain, and an acyl carrier protein 
(ACP domain) - is the minimum requirement for one elongation step (see Figure 1.4A) but 
further domains can be introduced into the module to modify the incorporated subunit.36  
In a typical elongation module consisting of KS-AT-ACP, the KS domain is acylated either 
with the starter unit or the growing polyketide chain from the previous module. The AT 
domain is responsible for the selection of the extender unit (most commonly malonyl- or 
methylmalonyl- CoA) and catalyzes its transfer to the acyl carrier protein (ACP). ATs of 
modular type I PKSs are often selective for extender units and are also able to select 
various unusual extender units like hydroxymalonyl-CoA, isobutyrylmalonyl-CoA, 
hydroxymalonyl-CoA and aminomalonyl-CoA.37–40 Selection of extender units can partly 
be predicted based on specific residues in the active site of the AT domain.41 Through a 
thioester linkage to the phosphopantetheine arm (ppant arm), the ACP domain is able to 
shuttle extender units and polyketide intermediates between the various domains. The 
ppant arm is a 4’-phosphopantetheine co-factor which is post-translationally attached to 
the active-site serine of the ACP apoenzyme via phosphopantetheinyl transferases 
(PPTases).42 The ACP domain docks to the acylated ketosynthase (KS) domain, where the 
magic of type I PKS happens. The KS domain catalyzes a decarboxylative condensation to 
form a carbon-carbon bond in a Claisen condensation step and thus builds up the carbon 
skeleton of the growing polyketide. The ACP shuttles the intermediate to processing 
enzymes such as a methyltransferase (MT) domain, which can transfer a methyl group to 
the -carbon, a ketoreductase (KR) domain, which can reduce the -keto group, a 
dehydratase (DH) domain, which can catalyze dehydration to yield a double bond 
between the  and the  carbon, and an enoyl-reductase (ER) domain, which can 
stereoselectively reduce the double bond. The ACP subsequently forwards the processed 
polyketide to the KS of a downstream module or a chain-releasing thioesterase (TE) 
domain. Only recently, researchers from the University of Michigan uncovered the 
structure of a whole PKS module by electron cryo-microscopy and thereby explained the 
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structural mechanism underlying the ACP shuttle machinery. It has been shown that the 
whole PKS module creates a reaction chamber for the ACP domain to allow the transport 
of building blocks and intermediates between the catalytic domains of one module.43,44 
The common starter units of type I PKS are malonyl- or methylmalonyl-CoA, but varying 
starter units enlarge the chemical diversity produced by PKS. Amino acid-derived short 
branched chain carboxylic acids like isobutyryl-CoA, 2-methylbutyryl-CoA or isovaleryl-
CoA as shown for the biosynthesis of the myxobacterial natural products myxothiazol45 
and the herein presented cystomanamides13 as well as cyclohexanecarboxylic acid as 
shown for the biosynthesis of manumycin-type antibiotics46–48 are two representatives for 
the extreme diversity of PKS starter units.49 
Although the modular PKS is the most abundant form in myxobacteria, myxobacterial 
biosynthetic pathways frequently show unusual genetic and biochemical features.27 The 
iteratively acting module in a modular type I PKS pathway in the stigmatellin 
biosynthesis in Stigmatella aurantiaca Sg a1550 is only one example for the unusual features 
found in myxobacterial pathways. 
1.2.2 Nonribosomal peptide synthetases (NRPS) 
Nonribosomally biosynthesized peptides are a class of peptide secondary metabolites that 
are characterized by some structural features. They can contain proteinogenic as well as 
non-proteinogenic amino acids like D-amino acids13 and ornithine51,52 and are often 
macrocyclic53 or branched macrocyclic54. They contain heterocyclic rings like thiazoline 
and oxazoline and they bear modifications like N-methylation, N-formylation, 
halogenation, hydroxylation, and glycosylation.55 Examples for unusual structures 
produced by NRPS in myxobacteria are the argyrins,53 myxovalargins56 and vioprolides57 
(see Figure 1.3). 
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Figure 1.3: Chemical structures of nonribosomal peptides from myxobacteria. 
NRPS show a modular structure with strong similarity to modular type I PKS but instead 
of carboxylic acids, amino acids serve as building blocks. In analogy to PKS, three 
domains are needed in a minimal NRPS module to accomplish one cycle of chain 
elongation (Figure 1.4B). The adenylation (A) domain is responsible for the selection of 
the substrate amino acid and for its activation as amino acid adenylate.58 A domains were 
found to bear highly conserved core motifs and Stachelhaus et al. identified ten amino 
acids residues by analysis of the binding pocket and comparison with other A domains to 
be responsible for the substrate specificity. Bioinformatics tools were developed based on 
this “Stachelhaus code” to predict the substrate specificity of A domains.59 The peptidyl 
carrier protein (PCP) domain, in analogy to the ACP domain from PKS, covalently binds 
the activated amino acid as a thioester to the ppant arm which then acts as a shuttle to 
reach the various catalytic centers.42 The condensation (C) domain recognizes on the one 
hand the growing peptide chain bound to the previous PCP domain and on the other 
hand the newly activated amino acid and catalyzes the amide bond formation to result in 
an elongated peptide chain.60 Various functional subtypes of the condensation domain 
exist that catalyze either the peptide bond between two L-amino acids, between D- and L-
amino acids, heterocyclization domains that catalyze both the amide bond formation as 
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well as the subsequent cyclization of cysteine, serine or threonine residues and dual 
epimerization / condensation domains that catalyze both the epimerization and amide 
bond formation. Recently, starter C domains were described that acylate the first amino 
acid with a -hydroxy-carboxylic acid.61 To produce the several hundred different 
building blocks found in NRPS products, a huge number of optional domains as well as 
modifying enzymes were identified up to date including optional domains responsible 
for epimerization (E), cyclization (Cy), oxidation (Ox), reduction (R), N-methylation (Mt) 
and formylation (F) as well as modifying enzymes for glycosylation, halogenation and 
reduction.62 
 
Figure 1.4: A: Three core domains are minimally required for one polyketide synthase module: an 
acyltransferase (AT) domain, an acyl carrier protein (ACP) domain and a ketosynthase (KS) 
domain. The AT domain selects the extender unit and attaches it to the phosphopantetheine arm 
(ppant arm) of the ACP domain. The acylated KS domain catalyzes the central Claisen 
condensation to form the C-C bond to connect the building blocks. B: In a similar fashion, the three 
minimally required domains in nonribosomal peptide synthetases are a condensation (C), an 
adenylation (A) and a peptidyl carrier protein (PCP) domain. The growing chain is recognized by 
the C domain while bound to the PCP domain of the previous module. The elongation unit is 
selected and activated by the A domain and attached to the ppant arm of the PCP domain. The 
condensation domain then catalyzes the amide bond formation (Figure modified from Khosla & 
Harbury, 200163). 
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1.2.3 Mixed PKS/NRPS hybrids 
One highlight in myxobacterial natural products is that their biosynthesis is frequently 
directed by mixed PKS–NRPS systems whereas for example actinomycetes and Bacilli 
predominantly synthesize pure PK or NRP natural products.64 Myxobacteria use the 
combination of both strategies to create a structural diversity unique in the world of 
natural products. They take advantage of the full chemical diversity by combining 
unusual carbon skeletons produced by PKS with the diverse structures produced by 
NRPS. The most prominent representatives of the mixed PK/NRP are the cytotoxic 
epothilones,65 but also the cystomanamides and macyranones presented in this thesis 
belong to the diverse and highly interesting group of mixed PKS/NRPS natural products 
(see Figure 1.5). 
  
Figure 1.5: Chemical structure of mixed PK/NRP natural products from myxobacteria. 
1.3 Improving Natural Product Discovery 
The above mentioned reasons explain the need to isolate new natural products and 
researchers around the world have been successful to identify a vast number of natural 
products. Nowadays, natural product chemists are facing a challenge since reisolation 
rates of already known secondary metabolites or derivatives thereof are increasing and 
the discovery rate of novel compounds is decreasing using conventional bioactivity-
guided isolation approaches. Low-abundant bioactive natural products, natural products 
with no or unusual bioactivity and products of silent gene clusters fall through the cracks 
             Introduction 22 
 
of a conventional screening approach. By the use of novel approaches that take advantage 
of recent developments in the diverse field of natural products research, novel scaffolds 
can still be isolated from myxobacteria and other sources that have not been analyzed 
before.  
What are the main factors that have changed in the recent years influencing natural 
product discovery? Approaches that are used to isolate new natural products can be 
assigned to three generic principles:  
I. Bioactive natural products can be isolated using a biological screening approach 
following the biological activity throughout the fractionation process 
(bioactivity-guided isolation).  
II. Genome mining can be used that allows the identification of biosynthetic gene 
clusters in the genome of an organism followed by the determination of the 
associated compound(s).  
III. The produced secondary metabolites can be screened by their chemical and 
structural features to allow the identification of new chemical entities. All three 
approaches share some working steps like the imperative necessity to isolate the 
new natural product and characterize it using different spectroscopic techniques 
including 1D and 2D NMR, HR-MS, and chemical derivatization but the way to 
get to this new natural product is widely differing (Figure 1.6). 
All three approaches profit from a wide range of investigated phylogenetic diversity since 
biodiversity is closely linked to the discovery of chemical diversity.66,67 The phylogenetic 
diversity is a measure for biodiversity based on evolutionary relationships and represents 
the variety of organisms. The screening of rare myxobacterial families and genera from 
geographically and ecologically promising habitats is therefore an encouraging method to 
discover novel natural products.68  
Apart from that, researchers have witnessed major technological advances within the 
fields in the last years that have led to improvements in the realization of all three 
principles. 
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Figure 1.6: Schematic workflow of the work steps of the introduced approaches to isolate new 
natural products. Green: biological screening; blue: chemical screening; red: genome mining, light 
gray: shared by two approaches, dark gray: shared by all three approaches. 
1.3.1 Biological screening 
The conventional bioactivity-guided isolation has been successful throughout decades. 
Myxothiazol, one of the first secondary metabolites from myxobacteria, was isolated in 
1980 by Reichenbach et al. using a paper-disc method against Mucor hiemalis to narrow 
down the antifungal activity of the crude extract.69 In a classical workflow, crude extracts 
are prepared from small-scale cultivation. These extracts are subjected to the primary 
biological screening to test it for e. g. antimicrobial, cytotoxic, or antiviral properties. 
Extracts are then fractionated by chromatographic techniques and the fractions are tested 
again in biological assays. Successive rounds of bioactivity-guided fractionation are 
necessary to narrow down the biological activity to one specific compound. Once the 
active target compound is identified, the microorganism is fermented in larger scale for 
subsequent purification and de novo structure elucidation as well as further bioactivity 
testing.  
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Major progress was made with respect to high-throughput screenings (HTS) to assay the 
biological activity using a wide range of organisms, cells, viruses, organelles and 
enzymes. Not only the availability of targets was enhanced but also the detection 
methods were developed further to include for example fluorescence cellular imaging70 
and luciferase-expression71 based systems. One of the main issues in the process is the 
complexity of crude extracts that complicates the development of robust HTS methods. 
Ingredients may interfere with the assay read-out (e. g. fluorescent or colored 
compounds), be insoluble or unstable or may cover the bioactivity of minor compounds.  
Another improvement in the field of bioactivity-guided fractionation represents the 
automated HPLC-MS fractionation where fractions can be trapped in HTS compatible 
96-well plates, a process that reduces the laborious workload of this screening approach. 
1.3.2 Genome mining 
With the fast-growing number of fully sequenced microbial genomes starting with the 
first complete genome sequence of Haemophilus influenzae in 1995,72 it became clear that 
the biosynthetic potential of microorganisms was largely underestimated. Even 
organisms that were previously not assumed to be secondary metabolite producers 
include huge biosynthetic gene clusters in their genomes and have the capacity to 
produce unknown natural products.73 The bioinformatics annotation of biosynthetic gene 
clusters made clear that also for myxobacteria, there is a large gap between known 
secondary metabolites from a strain and the amount of present secondary metabolite gene 
clusters.74 Under laboratory conditions, a large portion of secondary metabolites is either 
not produced or the amount is too small for identification. Besides the genome-
independent approaches of varying the culture conditions75 and co-cultivation with other 
organisms,76 the genetic manipulation of genes responsible for gene regulation77,78 is a 
potential target to enable production of the respective secondary metabolites. Another 
promising method is the heterologous expression of an unknown biosynthetic pathway in 
a convenient heterologous host to identify new natural products.79 This approach requires 
a detailed knowledge of biosynthetic secondary metabolite pathways as well as the 
development of efficient tools to unravel the biosynthetic machinery.  
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1.3.3 Chemical screening 
Natural products possess an enormous chemical and structural diversity so that they 
represent a rich source of novel molecular scaffolds. The chemical screening approach 
allows the search for interesting structural elements irrespectively of biological activity. 
The focus lies on the identification of new scaffolds in a structure-guided isolation since 
new scaffolds are closely related to finding novel modes of action as exemplified by the 
FabF inhibitor platensimycin isolated from Streptomyces platensis.80 Another example 
where a natural product goes hand in hand with the discovery of a new mechanism of 
action is argyrin A, a cyclical peptide derived from Archangium gephyra.53 The 
myxobacterial compound acts by stabilizing the cyclin kinase inhibitor p27kip1, a tumor 
suppressor protein.81  
The success of the chemical screening approach highly depends on the quality of the 
analytical techniques, it benefits from modern state-of-the-art LC-MS instrumentation as 
well as a highly sensitive NMR platform. The traditional way of studying chemical 
features of natural products includes fractionation of an extract based on 1H-NMR, 
isolation of the compound by liquid chromatography and structure elucidation using 
various spectroscopic methods (NMR-guided isolation). More recently, the trend is 
towards hyphenated techniques. The development of hyphenated techniques that 
combine the separation of compounds using liquid chromatography (LC) with nuclear 
magnetic resonance (NMR) spectroscopy were already started in the 1970s, where the first 
stopped-flow application was shown.82 Up to now, LC-NMR with on-flow, stopped-flow 
and loop-storage procedures were successfully installed,83 but a major development in the 
field was the use of solid-phase extraction (SPE) systems at the interphase of LC and 
NMR.84 The increasing NMR spectrometer field strength and methods for adequate 
solvent suppression also contributed substantially to the development of applicable 
systems.85,86 
Liquid chromatography (LC)-solid-phase extraction (SPE)-nuclear magnetic resonance 
(NMR)-mass spectrometry (MS) coupling, short LC-SPE-NMR-MS, became a key 
technique used to screen complex crude extracts for novel natural products with 
interesting structural features. It allows for rapid insights into structural elements of an 
unknown compound present in minute quantities. Even if the technique is in most cases 
not suitable for the full structure elucidation of complex natural products, the laborious 
and time-consuming pre-fractionation and isolation of known or uninteresting 
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compounds can be circumvented by taking advantage of the full flexibility regarding 
chromatographic conditions and NMR acquisition methods.84  
The concept of the hyphenated technique is to collect as many information as possible in 
one individual operation. The complex starting material is injected into the LC system, 
where a separation of the compounds is achieved in a reversed-phase HPLC system. 
Peaks are detected using UV as well as high-resolution MS detection. The process 
involves the addition of water to the mobile phase via a make-up pump after elution from 
the LC column to allow retention of the target compound on the cartridge. The system 
allows the trapping and enrichment of compounds on the cartridges by multiple 
subsequent chromatographic injections. The compounds are then dried with nitrogen gas 
and eluted with an appropriate deuterated solvent, typically acetonitrile-d3 or 
methanol-d4 to achieve a high spectral quality. Through a capillary system, the 
compound is pumped directly into the NMR flow probe for data acquisition (Figure 1.7). 
The development of cryogenic flow probes highly improved the technique.87 
 
Figure 1.7: Schematic illustration of the LC-SPE-NMR-MS process 
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1.4 Structure Elucidation of Natural Products 
50 years ago, structure elucidation of unknown compounds required decomposition into 
known fragments or total chemical synthesis to corroborate proposed structures. Gram 
quantities and years of tedious effort were needed to get insights into (often mistaken) 
structures.88 Nowadays, the time to characterize an unknown compound has decreased 
dramatically and also the amount of sample required for this purpose has decreased, 
depending on the complexity of the structure sometimes to less than 1 mg.  
Commonly, de novo structure elucidation is a task for nuclear magnetic resonance 
spectroscopy even though methods like infrared spectroscopy and X-ray crystallography 
are also useful to complement data obtained from NMR. Another standard analytical 
technique used in the full de novo structure elucidation of unknown secondary metabolites 
is mass spectrometry. It is useful to determine the elemental composition of a molecule as 
well as gaining insights into partial structures using MSn experiments.89  
1.4.1 Nuclear magnetic resonance (NMR) spectroscopy 
NMR is the most powerful and informative analytical tool in natural products chemistry 
with a wide range of applications. The spectroscopic technique underwent an enormous 
development since its first description by Isidor Rabi in 1938.90 The technique uses the 
magnetic properties of certain nuclei and has become an indispensable part of 
pharmaceutical research.91 Several advances of the technique have been awarded with the 
Nobel Prize (see Table 1.1).  
Table 1.1: List of Nobel Prize winners with scientific contributions concerning NMR 
(http://www.nobelprize.org) 
Nobel Prize winners Year Contribution 
Otto Stern 1943 discovery of the magnetic moment of the proton 
Isidor Rabi 1944 first NMR measurements 
Felix Bloch 
Edward M. Purcell 
1952 expanding the technique for use on liquids and solids 
Richard R. Ernst 1991 development of high resolution NMR spectroscopy 
Kurt Wüthrich 2002 
development of NMR-methods for 3D protein 
structure determination 
Paul C. Lauterbur 
Peter Mansfield 
2003 discoveries concerning magnetic resonance imaging 
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Since the first commercial spectrometer from Varian with 30 MHz became available in 
1952, the technique underwent manifold developments concerning pulse sequences, 
acquisition, processing methods and particularly hardware. Whereas the continuous 
wave (CW) mode was applied in the beginning of the technique that especially restricted 
the ability to obtain 13C spectra, pulsed Fourier transform NMR92,93 (FT-NMR) 
spectroscopy is the state of the art nowadays.94 The resonances are not anymore measured 
using a fixed magnetic field and sweeping the frequency of the electromagnetic radiation 
but all nuclei are excited at the same time by a short radio frequency pulse. After the 
radio frequency pulse, the exited nuclei emit the absorbed radiation causing a signal. The 
free-induction decay (FID) is recorded as a function of ‘time after the pulse’. The FID 
contains the sum of NMR responses from all the exited nuclei with a superposition of all 
excited frequencies, resulting in a time-domain signal. This signal cannot be interpreted 
directly but it is possible to extract the individual resonance frequencies and to convert 
the signal into the familiar frequency domain spectrum using a mathematical operation, 
the Fourier transformation (Figure 1.8). Since the signal contains information on all 
resonance frequencies in a single measurement in contrast to CW measurements, the 
signal can be repeatedly measured in a shorter time and summed up resulting in an 
increased signal to noise ratio compared to the CW measurements. This allows the 
structural analysis of much smaller amounts of compound as well as measurements of 
low abundant isotopes like carbon-13.95 Another important benefit and a direct 
consequence from the introduction of FT-NMR was the development of multiple pulse 
sequences in 1976 that greatly increased the applicability of NMR for natural product 
studies.96  
 
Figure 1.8: The diagram shows an FID signal from proton-nuclei obtained with the PFT technique. 
By Fourier transformation (FT), the time-domain signal is transformed into the frequency domain 
signal resulting in the 1H-NMR spectrum. 
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Breton and Reynolds97 nicely summed up the points that dramatically lowered the 
necessary amounts of samples for structure elucidation since 1984:  
- New pulse sequences 
- Higher field magnets due to the development of superconducting alloys 
- Cryogenic probes with enhanced sensitivity 
- Increased speed and power of computers 
- Improvements in electronic components 
- Development of superconducting alloys  
As a result, high field magnets up to 1 GHz and cryogenic probes are nowadays 
improving the sensitivity of the technique to allow the full structure elucidation of natural 
products often accessible in minimum quantities.98 The non-invasive and non-destructive 
nature of the technique raises the utility for natural products chemistry despite its 
inherent low sensitivity compared to optical spectroscopic methods. For the 
determination of the molecular structure of natural products, different NMR experiments 
are useful including one-dimensional NMR experiments as well as two-dimensional 
homo- and heteronuclear correlation experiments. Only the combination of different 
experiments allows it to piece together the structural information to unequivocally 
characterize a new natural product. 
1.4.1.1 One-dimensional NMR (1D NMR) 
For natural product chemists, there are two 1D NMR experiments commonly used to 
characterize small molecules, the proton (1H) NMR and the carbon (13C) NMR. 1D NMR 
spectra are relatively simple to analyze compared to two-dimensional spectra but provide 
high information content.  
The 1H NMR allows the identification of hydrogen atoms in an organic molecule. The 
chemically different protons in an organic molecule experience a different magnetic field 
depending on their chemical environment. There are basically three parameters99 that can 
be extracted from the proton spectrum: 
1) The chemical shift from a signal allows precise conclusions concerning the 
neighborhood of this hydrogen and its association with functional groups.  
2) The splitting pattern, so the fine structure of a signal, gives information about the 
number of neighboring spin-coupled (hydrogen) nuclei of the protons causing the 
signal as well as about the geminal and vicinal H, H coupling constants. Since the 
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vicinal 3J(H,H) coupling constants highly depend on the dihedral angle as 
formulated by Karplus, they provide important information for the 
conformational analysis of molecules (see also 1.4.1.2).100 
3) The intensity of resonance signals gives information about the number of 
chemically equivalent protons that cause a signal and can be measured by 
integration. Besides the information about the number of protons, the intensity of 
the signals also allows the quantitative analysis for example of different 
components in natural products mixtures. 
13C-NMR is a useful tool but the experiment is much less sensitive than 1H NMR for two 
reasons: The low natural abundance of the 13C isotope with only 1.1 % of all natural 
carbon is the first reason for the low sensitivity. Since the most abundant 12C isotope has a 
spin quantum number of zero and is therefore NMR silent, only the low abundant 13C 
isotope with a spin quantum number of ½ can be observed. Secondly, the intrinsic 
sensitivity of the 13C isotope, expressed by the gyromagnetic ratio, is only around 1/4th of 
the proton adding up to a relative sensitivity to the proton observation of about 
1.76 X 10-4.  
To simplify analysis of the 13C spectra and to avoid dividing the already low intensities of 
the 13C signals into multiplets due to coupling with hydrogen nuclei, 1H broad-band 
decoupling is commonly used. In a proton-decoupled spectrum, all carbons appear as 
single peaks. As a result, the intensity is largely increased and the spectra recorded by this 
method contain only one parameter, the chemical shift.101  
The editing of 13C spectra based on the number of attached protons can be very helpful to 
gain more information from the spectra. APT,102 INEPT103 or DEPT104 spectral editing 
sequences can be used to allow the differentiation of methyl, methylene, methine and 
quaternary carbons. The APT sequence provides partial spectral editing to discriminate 
methylene or quaternary carbons from methyl or methine carbons but with a lower 
sensitivity of the experiment. INEPT and DEPT sequences only give peaks for protonated 
carbons but therefore, due to polarization transfer, are significantly more sensitive 
compared to standard 13C measurements.97 
1D 13C NMR can often be avoided by using more sensitive proton-detected heteronuclear 
2D experiments providing both carbon shift data and correlation information. The 
advantage of proton-detected experiments is increased by the use of an inverse probe that 
is optimized for the 1H detection.105 
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1.4.1.2 Two-dimensional NMR (2D NMR)99,101 
With the introduction of two-dimensional experiments,96 structure elucidation using 
NMR has begun to replace the structure elucidation by chemical synthesis or 
decomposition into known fragments and became the method of choice for natural 
products chemistry. The use of 2D NMR experiments significantly increased the amount 
of information which can be extracted from the complex spectra.  
Homonuclear 1H-1H correlation experiments are the most frequently used ones providing 
both a high degree of sensitivity and excellent information content. The 1H,1H-COSY 
(Correlation SpectroscopY), that was the first two-dimensional sequence proposed, 
correlates the chemical shifts of two protons which are separated from each other with 
two, three and rarely four chemical bonds.106 A correlation assumes the spins to share a 
mutual J-coupling. The 2D-TOCSY (TOtal Correlation SpectroskopY) or HOHAHA 
(HOmonuclear HArtmann-HAhn) experiment allows to identify all protons belonging to 
a common coupled spin system.107 The experiment is based on magnetization transfer 
along a sequence of coupled protons and depends on sizes of 1H, 1H couplings. In case of 
strongly overlapped proton signals, a hybrid HSQC-TOCSY experiment can be useful that 
relies on the 13C resolution but at a large cost in sensitivity.108 
Heteronuclear 1H-13C experiments are extremely useful in structure elucidation of natural 
products, since most compounds consist of a carbon-hydrogen skeleton. With a loss of 
sensitivity, the heteronuclear experiments can also be used for proton correlation to other 
heteroatoms like 15N. Early heteronuclear experiments were acquired by 13C detection 
(13C-1H experiments) using the HETCOR sequence.109 However, because of the sensitivity 
advantages of 1H detection, 1H detected experiments like HSQC110 and HMQC111 have 
established themselves. The heteronuclear 2D NMR experiment 1H,13C-HSQC 
(Heteronuclear Single Quantum Coherence), that gives a better signal/noise ratio 
compared to the HMQC experiment, utilizes one-bond couplings and hence identifies 
directly connected nuclei. While a combination of 1H,1H COSY and 1H,13C HSQC 
correlations would already be sufficient to solve the structure of molecules exclusively 
composed of protonated carbons, one type of spectrum is missing to provide the final tool 
for the determination of complex natural products. The heteronuclear 2D experiment 
1H,13C-HMBC (Heteronuclear Multiple Bond Correlation) closes this gap by providing 
correlation spectra for detection of protons and carbons separated from each other with 
two, three or in special cases four chemical bonds.112 
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Whereas the already mentioned 2D NMR experiments map specifically through-bond 
interactions, the so called scalar couplings, additional experiments can also provide 
information about correlations through space (dipolar couplings) giving rise to the nuclear 
Overhauser effect (NOE) that causes changes in the resonance intensities. Since the NOE 
are only observed between those spins that are close in space (< 5 Å apart), it is important 
in modern structure elucidation providing information about the 3D geometry of a 
molecule. 2D-NOESY113 (Nuclear Overhauser Effect SpectroscopY) and 2D-ROESY114 
(Rotating frame nuclear Overhauser Effect SpectroscopY) are the most widely used 
techniques to uncover the spacial interactions. The 2D-ROESY is more applicable for 
natural products research due to its independency of the size of a molecule.  
Both techniques are used for J based configuration analysis115 to gather information about 
the relative configuration of two neighbored stereocenters in a flexible molecule. The 
method uses both, 1H-1H and 1H-13C coupling constants, to assign anti or gauche 
relationships of vicinally substituted carbon chains. The combination with NOE allows 
the determination of the conformation of adjacent asymmetric centers often found in 
natural products. 
1.4.2 Dereplication 
The successful identification of unknown secondary metabolites requires the recognition 
of already studied compounds to eliminate them from further processing within the 
screening and to avoid repeated characterization. The underlying operation called 
dereplication is a key process in natural product screenings. The goal is to detect the 
known compounds as early as possible in the screening of myxobacterial strains in order 
to concentrate on promising unknown natural products. This is becoming increasingly 
important with growing reisolation rates. Since the same metabolites are often produced 
by multiple strains, dereplication already plays a fundamental role in the strain selection 
for discovery programs to save time to concentrate on producers of novel secondary 
metabolites.  
Dereplication is done in different ways beginning from ring binders containing printouts 
of proton NMR or UV spectra for a manual comparison (personal experience) through the 
use of commercial data bases like SciFinder116 and MarinLit117 for comparison of 
molecular formulas or partial structures. It goes up to the use of mass spectral libraries 
like the MassBank,118 a public repository of mass spectra of small chemical compounds for 
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life sciences, or the Myxobase,119 that was developed for the efficient dereplication of 
myxobacterial secondary metabolites.  
Myxobase contains a chemical compound database, where the dereplication is done based 
on the comparison of different features measured in a defined analytical system. The 
retention time, high-resolution m/z value and isotope pattern fit are used to compare 
secondary metabolites to compounds in the database. The system highly depends on the 
reproducibility of the measured features and is only as good as the quality of the applied 
analytical techniques. A metabolite profiling using HPLC/HRMS in combination with an 
appropriate database can therefore be used for dereplication as well as for strain selection. 
Also the previously described LC-NMR technique is a tool to accomplish the 
dereplication of natural products and is especially useful for compounds were the data 
from LC-MS do not allow the confident identification.120  
1.5 Outline of the Study 
The main topic of this work was the metabolic profiling of the myxobacterial strain 
Cystobacter fuscus MCy9118. The myxobacterium showed a wide range of biological 
activity and was therefore prioritized in the screening process. The goal was to unravel 
the full chemical diversity provided by this natural product producer. Although the 
identification of derivatives of known compounds is of significant importance, our aim 
was to identify novel basic structures ideally exhibiting new modes of action. To realize 
this goal, a structure based screening approach was chosen that relies on the use of high-
end analytical techniques like HR-MS-based dereplication and LC-SPE-NMR-MS for the 
identification of new structural scaffolds. In the course of this screening, two new 
compound classes were identified besides several known antibiotics like althiomycin, 
roimatacene and myxochelin A and B.  
The first parts of both Chapters 2 and 3 report the studies concerning the identification 
and structure elucidation of the new compound classes named cystomanamides and 
macyranones. Their structures were elucidated by detailed analysis of the 1D and 2D 
NMR as well as MS/MS data and chemical derivatization. The cystomanamides are 
lipopeptides characterized by -hydroxy amino acids along with 3-amino-9-
methyldecanoic acid. The fatty acid residue is N-glycosylated in cystomanamide C and D. 
The macyranones are characterized by the presence of a rare 2-methylmalonamide moiety 
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in the peptidic backbone and an α-amino ketone fragment including an α’,β’-epoxyketone 
in macyranone A.  
The next aim of this thesis was to increase the knowledge of bacterial secondary 
metabolite biosynthesis. In-depth genome sequence analysis of C. fuscus MCy9118 gave 
first insights into the biosynthesis of the new natural products. Confirmation of the 
biosynthetic gene clusters identified as PKS/NRPS hybrids was achieved by gene 
deletion using a single crossover homologous recombination strategy which resulted in 
the abolishment of the production in both cases. Studies concerning the identification and 
confirmation of the cystomanamide and macyranone biosynthetic gene clusters are 
reported in the second part of both Chapters 2 and 3.  
In order to study the biological activity of the isolated compounds, they were tested 
against a broad range of enzymes, bacteria, fungi, parasites and mammalian cell lines. 
Macyranone A was found to inhibit the eukaryotic 20S proteasome and to be active 
against the parasitic agents Trypanosoma brucei rhodesiense and Leishmania donovani. The 
results of these studies concerning the biological activity of macyranone A are illustrated 
in Chapter 3. 
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2 Cystomanamides 
2.1 Abstract 
Cystomanamides A-D were isolated as novel natural product scaffolds from Cystobacter 
fuscus MCy9118 and their structures were established by spectroscopic techniques 
including 2D NMR, LC-SPE-NMR/-MS and HR-MS. The cystomanamides contain -
hydroxy amino acids along with 3-amino-9-methyldecanoic acid that is N-glycosylated in 
cystomanamide C and D. The gene cluster for cystomanamide biosynthesis was identified 
by gene disruption as PKS/NRPS hybrid incorporating an iso-fatty acid as starter unit 
and including a reductive amination step at the interface of the PKS and NRPS modules. 
2.2 Main Text 
Myxobacteria have proven to exhibit a fascinating capacity to produce chemically 
intriguing natural products which often show unique structural elements rarely produced 
by other sources.1 Myxobacterial secondary metabolites belong to multiple structural 
classes and many of these diverse compounds originate from mixed polyketide-
nonribosomal peptide biosynthetic pathways.2 Complex multimodular enzymes 
involving various catalytic and structural domains are responsible for the biosynthesis of 
these versatile structures.3 The ability to generate a wide range of complex natural 
products is expanded by enzymes introducing β-branching and post-PKS and NRPS 
reactions such as hydroxylation, glycosylation and epimerization.4  
Our discovery strategy to determine natural products with novel structural frameworks 
includes UHPLC/HRMS-based metabolomics for strain selection and dereplication as 
well as hyphenated chromatographic methods such as LC-SPE-NMR/-MS for isolation 
driven by chemical and structural features. This approach indicated the presence of 
unusual peptides in an extract of Cystobacter fuscus MCy9118 and finally led to the 
isolation of a new family of lipopeptides, the cystomanamides (ctm).  
These new linear peptides comprise exclusively non-proteinogenic amino acids and bear 
an unusual 3-amino-9-methyldecanoic acid residue at the N-terminus. Cystomanamide C 
and D contain an N-linked glycosylation, which is one of the rare examples of late-stage 
modification reactions of myxobacterial metabolites.5 In addition to these four new 
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myxobacterial natural products, the strain was also found to produce the known 
antibiotics althiomycin6,7, roimatacene8 and myxochelin A9 and B10.  
HRESIMS of cystomanamide A (1) displayed an [M+H]+ peak at m/z 609.3248 (calcd for 
C28H45N6O9, 609.3243), consistent with the molecular formula C28H44N6O9 containing 10 
double-bond equivalents (DBE). The 1H NMR spectrum of cystomanamide B in CD3OD 
exhibited signals characteristic of a peptide including three α-proton signals at δ 4.77 (1H, 
dd, J = 7.4, 6.3 Hz), 4.80 (1H, d, J = 3.75 Hz) and 4.49 (1H, d, J = 3.25 Hz). Moreover, a 
downfield pair of triplets at δ 7.28 (2H, t, J = 7.45 Hz) and 7.20 (1H, t, J = 7.45 Hz) and a 
doublet at δ 7.34 (2H, d, J = 7.45 Hz) were observed (see Table S4). The HSQC spectrum 
revealed the presence of several methylenes between δH 1.2 and 2.9 and two oxygenated 
methines at δC 72.8 / δH 4.29 (β-OH-Asn) and δC 74.9 / δH 5.22 (β-OH-Phe).  
A detailed analysis of the 2D NMR data obtained from HSQC, HMBC, COSY and TOCSY 
experiments indicated the presence of asparagine, β-hydroxy asparagine (β-OH-Asn) and 
β-hydroxy phenylalanine (β-OH-Phe). Additionally, a 3-amino-9-methyldecanoic acid 
residue (AMDA) was identified and its partial structure was deduced as follows. A 
sequential spin system starting from two methyl groups at δ 0.89 (Me-10 and Me-11AMDA) 
attached to a methine at δ 1.55 (H-9AMDA) and comprising five sequential methylene 
groups H2-8 to H2-4 was obtained from COSY and TOCSY correlations. COSY correlations 
extended this fragment by an additional aminomethine group at δ 3.54 (H-3AMDA) 
followed by a methylene at δ 2.68, 2.50 (H2-2AMDA). Finally, HMBC correlations from H-
3AMDA and H2-2AMDA to a carbonyl resonance at δ 173.2 (C-1AMDA) clearly indicated that 
AMDA represents a β-amino acid. The sequence was established through HMBC 
correlations from α-protons to carbonyl carbons of adjacent residues to result in the 
sequence: AMDA-Asn-(β-OH-Asn)-(β-OH-Phe). Long-range HBMC correlations from the 
α-proton at δ 4.77 (H-2Asn) to C-1AMDA connected AMDA to the N-terminus of asparagine, 
thereby completing the structure of 1 as linear tetrapeptide.  
HRESIMS of cystomanamide B (2) displayed an [M+H]+ peak at m/z 860.4039 (calcd for 
C40H58N7O14, 860.4036), consistent with the molecular formula C40H57N7O14 containing 16 
DBE. The 1H NMR spectra of 2 in comparison to that of 1 exhibited additional signals for 
one α-proton at δ 4.43 (1H, dd, J = 7.5, 5.5 Hz) and two downfield doublets at δ 7.05 (2H, 
d, J = 8.4 Hz) and δ 6.68 (2H, d, J = 8.4 Hz). The HSQC spectrum revealed the additional 
presence of one methylene at δC 38.2 / δH 3.12, 2.97 (Tyr), one oxygenated methylene at δC 
67.9 / δH 4.32, 4.16 (glyceric acid GA) and one oxygenated methine at δC 71.0 / δH 4.24 
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(GA). This evidence in combination with the DQF-COSY and HMBC correlations 
indicated that in comparison to 1, cystomanamide B bears an additional glyceric acid 
(GA) and tyrosine residue. HMBC long range correlations from α-protons to carbonyl 
carbons of adjacent residues and from the methylene protons H2-3GA to C-1 -OH-Phe 
resulted in the linear depsipeptide 2 with the sequence AMDA-Asn-(β-OH-Asn)-(β-OH-
Phe)-GA-Tyr.  
The ESI-MS/MS fragmentation patterns of cystomanamide C (3) and D (4) indicated a 
glycosylation. More precisely, 3 showed the loss of a 162 mass units fragment compared 
to 1 suggesting the presence of a hexose residue. The 1H NMR and HSQC spectra in 
comparison with those of 1 showed various additional signals between 3.1 and 4.2 ppm 
with different intensities belonging to three rotamers of a sugar moiety. Based on HMBC 
and ROESY NMR data, the sugar residue was identified as fructose with β-D-
fructopyranose as the most abundant rotamer, a sugar moiety also found in kwansonine 
A and B.11 The HMBC spectrum showed a key correlation from the methylene at δ 3.27 
(H-1FRU) to the aminomethine at δ 3.59 (H-3AMDA) indicating an N-linked glycosylation of 
the β-amino fatty acid chain. Brabantamides are another example for compounds 
showing a sugar attached to a fatty acid derived moiety.12  
Cystomanamide D showed similar NMR and MS data with a mass difference of 16 Da 
compared to 3 that was explained by the absence of the β-hydroxylation of the 
phenylalanine residue.  
The absolute configuration of the amino acid residues was elucidated by MS detected 
chromatographic analysis of the L- and D-FDLA (1-fluoro-2,4-dinitro-phenyl-5-L/D-
leucinamide) derivatives of the acid hydrolyzate of cystomanamide A, B and C and 
comparison with respective standards.13 The amino acid residues were assigned as 
D-asparagine, L-erythro-β-OH-asparagine, D-threo-β-OH-phenylalanine and D-tyrosine. 
The R configuration of C-3 of the AMDA residue was also determined by this method. β-
Amino fatty acids derivatized with Marfey’s reagent show a behavior analogue to α-
amino acids where the L series elutes earlier than the D series.14 The D configurations of 
glyceric acid in 2 and the fructose in 3 were both established by chiral HPLC of the acid 
hydrolyzate and comparison with respective standards.  
Based on the chemical structures of the cystomanamides (see Figure 2.1), it seemed likely 
that these compounds are products of a PKS/NRPS hybrid megasynthetase. Genome 
sequence data of C. fuscus MCy9118 were generated using Illumina sequencing. A 
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retrobiosynthetic approach in combination with antiSMASH 2.015 analysis of the draft 
genome sequence led to the identification of the ctm biosynthetic gene cluster. The 
predicted gene cluster consists of 10 open reading frames (ORFs) and has an overall GC 
content of 69.8%.  
 
Figure 2.1: Structures of cystomanamide A (1), B (2), C (3), D (4) 
To further analyze the catalytic domains and the A domain substrate specificity, the open 
reading frames were translated and analyzed using Pfam16, NRPS predictor217, and 
PKS/NRPS Analysis18. This analysis led to the prediction of one loading module, six 
elongation modules and one termination module. Genes not resulting in predictions 
related to PKS or NRPS domains were analyzed via the BLAST algorithm19 using the non-
redundant sequence database at the National Center for Biotechnology Information 
(NCBI). CtmA encodes for a complex protein that contains functional domains belonging 
to fatty acid synthases, polyketide synthases, amino transferases and non-ribosomal 
peptide synthetases. The gene shows similarity to mycA encoding for mycosubtilin 
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synthase subunit A.20 Feeding experiments with L-[methyl-2H3]leucine indicated a 
leucine-derived branched chain carboxylic acid starter unit.21 The assembly line starts 
with a CoA ligase domain responsible for recognition and activation of the starter 
molecule 9-methyldecanoic acid, an iso-odd fatty acid (see Figure 2.2). The activated 
substrate is then transferred to the first acyl carrier protein in the loading module.22 It 
undergoes one elongation step using malonate as a substrate to form the -ketothioester. 
The amino transferase domain (AMT) located in module 1 at the interface of the PKS and 
NRPS modules next reductively aminates the β-ketothioester which is then passed on to 
the NRPS module as shown for mycosubtilin biosynthesis.23 This AMT shows significant 
(57 %) similarity to the AMT found in MycA. It was proven in vitro that the AMT 
catalyzes amine transfer from an amino acid to a protein-bound β-ketothioester to 
generate the corresponding protein-bound β-aminothioester dependent on pyridoxal 5’-
phosphate (PLP).23 Biosynthesis continues with three NRPS based reaction cycles. In silico 
analysis of the A domain specificities is consistent with the incorporated amino acids. 
Module 2, 4 and 6 contain epimerization domains that are responsible for the 
transformation of the L- into the respective D-amino acid. The incorporation of D-Asn, D-
Phe and D-Tyr are in accordance with the structure and the absolute configuration of 2. 
The second NRPS module, module 3, is split into two proteins, CtmA and CtmC, which 
can be regarded as unusual but is not unprecedented.22 The condensation domain is 
encoded by ctmA whereas the adenylation domain and the peptidyl carrier protein are 
encoded by ctmC. The module bears an additional condensation domain encoded by 
ctmC, which seems to be inactive due to the missing catalytic histidine residues in the 
active site.24 Genetically, the module is separated by ctmB whose product is homologous 
to TauD from Streptomyces auratus (44.9%), a well-studied non-heme iron hydroxylase. 
CtmB contains the conserved 2-His-1-carboxylate facial triad responsible for iron 
binding25,26 as well as the conserved Arg residue that ligates β-ketoglutarate.27 It also 
shows similarity (35.1%) to SyrP from Pseudomonas syringae, which is responsible for the 
β-hydroxylation of an aspartyl residue in syringomycin E biosynthesis.28 This indicates 
that CtmB is most likely responsible for the hydroxylation of the second asparagine 
residue to form L-erythro-β-OH-asparagine. Module 5 has a similar organization as NRPS 
modules but instead of an adenylation domain it contains an unusual domain that 
exhibits the three conserved motifs specific for the HAD superfamily.29 
  
 
Figure 2.2: Gene cluster of cystomanamides in Cystobacter fuscus MCy9118 and the biosynthetic pathway of 2. 
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BLAST results show similarity to FkbH30 from Streptomyces hygroscopicus subsp. 
ascomyceticus (29.5 %) and OzmB31 from Streptomyces albus (30.6 %) which are responsible 
for the formation of glyceryl-ACP in the biosynthesis of the polyketide natural products 
FK520 and oxazolomycin. For OzmB it was demonstrated that it acts as a bifunctional 
glyceryl transferase/phosphatase that first binds D-1,3-bisphosphoglycerate from the 
glycolytic pool to form the D-3-phosphoglyceryl-S-OzmB intermediate. In the next step it 
removes the phosphate group to receive the D-3-glyceryl-S-OzmB species (acting as a 
phosphatase), and finally it acts as glyceryl transferase by transferring the glyceryl group 
to an acyl carrier protein (ACP).31 To the best of our knowledge, CtmD is the first protein 
containing such a domain integrated into an NRPS module underlining the enormous 
potential of these modular megaenzymes for combinatorial biosynthesis.  
Although the condensation domain of module 5 is homologous to the typical amide-
forming condensation domains, it most likely catalyzes the formation of an ester bond 
instead of a peptide bond. The biochemical evidence for condensation domains being able 
to catalyze ester bond formation was given in studies concerning the mycotoxins 
fumonisins and the antitumor antibiotic C-1027.32,33 The same mechanism with C domains 
embedded in elongation modules that are responsible for chain extension via ester bond 
formation has been proposed for the biosynthesis of some other nonribosomal 
peptides.34-36 
The last step in the biosynthesis of the cystomanamides is the incorporation and 
epimerization of tyrosine in module 6. The assembly line is terminated by a thioesterase 
domain that releases the product to receive the linear PKS/NRPS product 2. The 
glycosylation of 3 and 4 requires enzymes encoded outside the aglycon cluster which 
could not be identified as 41 genes were annotated as glycosyltransferase in the genome 
of Cystobacter fuscus MCy9118.  
To further confirm that the candidate gene cluster is responsible for biosynthesis of the 
cystomanamides, the PKS/NRPS gene ctmA was inactivated using a single crossover 
homologous recombination knockout strategy. The resulting ctmA mutant lost the ability 
to produce 1 as well as its analogues (see Figure S4 and S5), therefore validating that the 
proposed gene cluster is indeed responsible for cystomanamide biosynthesis.  
To explore the relation of the surrounding open reading frames in the biosynthetic 
pathway, we inactivated orf2, orf4 and orf5. Cultivation of the resulting orf2 and orf4 
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mutants and subsequent HPLC analysis revealed that inactivation of both genes 
abolished production of 1 and its analogues (see Figure S4 and S5). The product of orf1 
shows similarity to JmjC domain containing proteins that are connected to transcription 
factors37, whereas the products of orf2, orf 3 and orf4 show similarity to the very 
heterogeneous group of β-lactamases. Orf1 to orf4 are most likely involved in the 
regulation of gene expression. At the same time, HPLC analysis of a cultivation of orf5 
mutants showed a cystomanamide production comparable to the wild type strain, 
indicating no or only a minor role of orf5 in the biosynthesis.  
The compounds were tested in various bioactivity assays including cytotoxicity against 
HCT-116 and CHO-K1 cells, antibacterial tests against various gram negative and gram 
positive bacterial strains, antifungal assays against Candida albicans and Mucor hiemalis 
and HIV-1 inhibition. Up to date, they have not shown biological activity. We continue 
functional testing to find the often very specific biological activity of these natural 
products and to further evaluate their biological function.  
In summary, we discovered a new family of glycosylated lipopeptides using a structure-
guided approach by LC-SPE-NMR. The compounds were fully characterized and a gene 
cluster responsible for cystomanamide biosynthesis was identified. Inactivation of three 
independent genes in this cluster completely abolished cystomanamide production in the 
mutants, verifying their essential role during biosynthesis. 
2.3 Supporting Information 
2.3.1 General experimental procedures 
Optical rotations were measured with a Jasco polarimeter, IR spectra were recorded on a 
Perkin-Elmer FT-IR Spectrum One spectrometer. NMR spectra were recorded in 
methanol-d4 on a Bruker Ascend 700 spectrometer with a 5 mm TXI cryoprobe (1H at 700 
MHz, 13C at 175 MHz). DQF-COSY, HOHAHA, HSQC, HMBC, and ROESY experiments 
were recorded using standard pulse programs. HSQC experiments were optimized for 
1JC-H = 145 Hz, and HMBC spectra were optimized for 2,3JC-H = 6 Hz. LC-HRMS data was 
performed on a Dionex Ultimate 3000 RSLC system using a Waters BEHC18, 100 x 2.1 
mm, 1.7 µm dp column. Separation of 2 µl sample was achieved by a linear gradient with 
(A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µl/min and 45 °C. The 
gradient was initiated by a 0.5 min isocratic step at 5 % B, followed by an increase to 95% 
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B in 18 min to end up with a 2 min step at 95 % B before reequilibration with initial 
conditions. UV spectra were recorded by a DAD in the range from 200 to 600 nm. The LC 
flow was split to 75 µl/min before entering the maXis HR-ToF mass spectrometer 
(BrukerDaltonics, Bremen, Germany) using the standard ESI source. Mass spectra were 
acquired in centroid mode ranging from 150 - 2000 m/z at 2 Hz scan speed. 
2.3.2 Cultivation of strain Cystobacter fuscus MCy9118 
Myxobacterial strain MCy9118 was isolated in 2007 from a Philippine soil sample using 
rabbit dung as bait. From the appearance of fruiting bodies on dung, the strain was 
purified by standard myxobacterial method of repeated subcultivations of the swarm 
colony on agar. Morphological characterizations of the strain combined with molecular 
phylogenetics led to the identification of strain MCy9118 to Cystobacter fuscus. To transfer 
the strain from solid medium to liquid medium and to grow the mutants, actively 
growing cells were excised from agar plates, inoculated into a 50 mL buffled flask 
containing 20 mL M medium (1 % phytone, 1 % maltose x H2O, 0.1 % CaCl2, 0.1 % MgSO4 
x 7 H2O, 25 mM HEPES, 8 mg/L Fe-EDTA adjusted to pH 7.2 with 10 N KOH) and 
incubated at 30°C for 2 days. For fast analysis of the secondary metabolite profile, 2 % 
(w/v) XAD adsorber resin (Amberlite XAD-7, Sigma) were added on day three and 
harvested after 4 h by centrifugation. The XAD/cell mixture was extracted with 5 mL 
methanol and analyzed by HPLC-MS.  
For best production of the cystomanamides, the preculture was used to inoculate two 1 L 
flasks containing 100 mL VY/2S (0.5 % Baker’s yeast, 0.5 % CaCl2 x 2 H2O, 1.0 % soluble 
starch, 5 mM HEPES adjusted to pH 7.0 with 10 N KOH) medium that were incubated at 
30°C for 8 h. 300 mL VY/2S medium were added into each flask and incubated at 30°C 
overnight. The cultures were used to inoculate a 10 L fermentor containing 8 L VY/2S 
medium (pO2 = 20 %; stirring rate 600rpm; 30°C; pH 7.0). 2 % (w/v) XAD adsorber resin 
(Amberlite XAD-7, Sigma) was added on day 2 of the fermentation and further incubated 
for 8 days. Cultures were harvested by sieving the culture to receive the XAD and 
subsequent centrifugation at 4000 rpm for 10 min at 20°C to receive the cells. The 
supernatant was discarded. 
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2.3.3 Isolation 
Cells and XAD from the 8 L culture were freeze dried overnight and extracted separately. 
To remove impurities, 2 x 200 mL hexane and 3 x 300 mL EtOAc were used. Extraction 
was accomplished with 3 x 300 mL MeOH to obtain a cell and an XAD extract with 2.0 g 
and 1.5 g, respectively. Cystomanamide A, C, and D were extracted from the XAD crude 
extract starting with two successive runs of sephadex fractionation. The sephadex 
fractionation was performed using a GE Healthcare SR 25/100 column and a 
TAC15/750G0-SR.2 column, sephadex LH 20 was used for separation and methanol as 
mobile phase. Subsequently, the fractions containing the peptides were purified by 
semipreparative HPLC (Phenomenex Synergi™ 4 µm Fusion-RP 80 Å, LC Column 250 x 
10 mm, DAD at 220 nm) eluting with a linear gradient of 10-100% MeOH/H2O + 0.1% FA 
in 50 min to afford compounds 1 (0.10 mg/L, tR = 27.1 min), 3 (0.09 mg/L, tR = 25.9 min) 
and 4 (0.02 mg/L, tR = 28.1 min).  
2 was extracted from the cell crude extract using sephadex fractionation (GE Healthcare 
SR 25/100 column, sephadex LH 20 with methanol as mobile phase) and subsequent 
purification by semipreparative HPLC (Phenomenex Synergi™ 4 µm Fusion-RP 80 Å, LC 
Column 250 x 10 mm, DAD at 220 nm) eluting with a linear gradient of 30-40% 
MeOH/H2O + 0.1% FA in 5 min followed by 40-80% MeOH/H2O + 0.1% FA in 40 min to 
afford compound 2 (0.04 mg/L, tR = 20.4 min). 
Cystomanamide A (1): Colorless amorphous powder; [α]20D + 18.4 (c 0.21, MeOH); IR 
(film) νmax 3299, 2960, 2931, 2866, 1664, 1593, 1393 cm-1; 1H and 13C NMR data, see Table 
S4; HRESIMS m/z 609.3248 [M+H]+ corresponding to a molecular formula C28H44N6O9 
(calcd for C28H45N6O9, 609.3243, Δ = 0.82 ppm)  
Cystomanamide B (2): Colorless amorphous powder; [α]20D + 13.2 (c 0.09, MeOH); IR 
(film) νmax 3287, 2946, 2325, 1676, 1593, 1389, 1350, 1032 cm-1; 1H and 13C NMR data, see 
Table S5; HRESIMS m/z 860.4039 [M+H]+ corresponding to a molecular formula 
C40H57N7O14 (calcd for C40H58N7O14, 860.4036, Δ = 0.35 ppm)  
Cystomanamide C (3): Colorless amorphous powder; [α]20D + 19.2 (c 0.07, MeOH); IR 
(film) νmax 3334, 2949, 1669, 1596, 1397, 1085, 1027 cm-1; 1H and 13C NMR data, see Table 
S6; HRESIMS m/z 771.3786 [M+H]+ corresponding to a molecular formula C34H54N6O14 
(calcd for C34H55N6O14, 771.3771, Δ = 1.94 ppm)  
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Cystomanamide D (4): Colorless amorphous powder; 1H and 13C NMR data, see Table S7; 
HRESIMS m/z 755.3829 [M+H]+ corresponding to a molecular formula C34H54N6O13 (calcd 
for C34H55N6O13, 755.3822, Δ = 0.93 ppm)  
2.3.4 Absolute configuration of glyceric acid 
 An aliquot (0.2 mg) of compound 2 was hydrolyzed with 6 N HCl (0.3 mL) for 16 h at 90 
°C. The hydrolyzate was concentrated to dryness and subjected to chiral HPLC analysis 
(Phenomenex Chirex 3126 (d)-penicillamine (150 x 4.6 mm) HPLC column; flow rate 1 
mL/min; UV detection at 254 nm; solvent 2 mM CuSO4:MeOH 85:15). The retention time 
of glyceric acid from the hydrolyzate with 18.7 min was compared to authentic standards 
whose retention times were 14.2 min for L-glyceric acid and 18.4 min for D-glyceric acid. 
2.3.5 Absolute configuration of fructose 
 An aliquot (0.4 mg) of compound 3 was hydrolyzed with 1.25 M HCl in methanol (0.5 
mL) for 16 h at 35 °C. The hydrolyzate was neutralized using 1 NaHCO3, concentrated to 
dryness and subjected to chiral HPLC analysis (Chiralpak IE (Daicel Chiral Technologies) 
5 µm (250 x 4.6 mm) HPLC analytical column; flow rate 1 mL/min; MS detection ranging 
from 150 to 1500 m/z; solvent hexanes (+0.1 % FA): ethanol (0.1 % FA) 80:20). The 
retention time of fructose from the hydrolyzate with 23.3 min was compared to 
hydrolyzed D- and L- fructose whose retention times were 22.9 min and 28.8 min, 
respectively. 
2.3.6 LC/MS analysis of L/D-FDLA derivatives 
Approximately 0.2 mg of compound 1, 2, and 3 were hydrolyzed with 6 N HCl (0.8 mL) 
and shaken at 90°C for 16 h. Samples were dried under vacuum and dissolved in H2O 
(100 µL). It was split into two 50 µL aliquots and 1 N NaHCO3 (20 µL) and 1% 1-fluoro-
2,4-dinitrophenyl-5-leucine-amide (L-FDLA or D-FDLA solution in acetone, 100 µL) were 
added respectively. The mixtures were heated to 40°C for 40 min, allowed to cool to RT 
and neutralized with 2 N HCl (20 µL). Solvents were evaporated to dryness under 
nitrogen and residues were dissolved in 1 mL CH3CN and analyzed by LCMS. All 
measurements were performed on a Dionex Ultimate 3000 RSLC system using a Waters 
BEH C18, 100 x 2.1 mm, 1.7 µm column by injection of 1 µl sample. Separation was 
achieved by a gradient using (A) H2O + 0.1% FA to (B) ACN + 0.1% FA at a flow rate of 
550 µl/min and 45 °C. The gradient was as follows: starting at 5 % B to increase to 10 % B 
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in 1 min, from 1 to 15 min increase to 35 % B, from 15 to 22 min increase to 50% B, from 22 
to 25 min increase to 80 % B. After a 1 min hold at 80 % B the system was reequilibrated 
with initial conditions for 5 minutes. UV data was acquired at 340 nm and MS–detection 
was performed simultaneously. Coupling the HPLC to the MS was supported by an 
Advion Triversa Nanomate nanoESI system attached to a Thermo Fisher Orbitrap. LC 
flow is split to 500 nL/min before entering the ion source. Mass spectra were acquired in 
centroid mode ranging from 150 to 1000 m/z at a resolution of R = 30000. Results can be 
found in Table S1. 
Table S1. Results of Marfey’s analysis of the cystomanamides compared to the respective standards 
 
detected 
m/z 
Cystomanamide A Cystomanamide B Cystomanamide C Standard 
L-FDLA D-FDLA L-FDLA D-FDLA L-FDLA D-FDLA L-FDLA D-FDLA 
AMDA 296.28 25.84 24.69 25.84 24.69 25.85 24.69 -- -- 
L-Asn 428.14 13.75 13.02 13.80 13.00 13.80 13.01 13.02 13.79 
erythro-β-OH-L-
Asn 
444.14 
12.51 12.07 12.54 12.08 12.50 12.08 12.47 12.03 
threo-β-OH-L-
Phe 
476.18 
19.61 15.76 19.63 15.75 19.60 15.76 15.74 19.60 
L-Tyr 476.18 -- -- 13.30 13.15 -- -- 13.15 13.31 
threo- β -OH-L-
Asn 
444.14 
-- -- -- -- -- -- 10.61 10.61 
erythro-β-OH-L-
Phe 
476.18 
-- -- -- -- -- -- 15.91 18.54 
 
2.3.7 Feeding experiments 
Cultivation of MCy9118 was performed in 50 mL VY/2S medium. The shake flask 
cultures were grown for 3 days. L-[5,5,5,-d3]leucine was dissolved in DMSO and 25 µL 
were added to the culture in two portions (after 1 h and 18 h) to a final concentration of 
0.2 mM. On day 3, 2 % (w/v) XAD adsorber resin (Amberlite XAD-7, Sigma) was added 
to the culture and the culture was harvested after 2h by centrifugation. The sediment was 
extracted with 5 mL MeOH for 30 min and filtered. The solvent was evaporated in vacuo 
and the residue was redissolved in 200 µL MeOH and analyzed by LC-HRMS. 
            Cystomanamides   54 
 
2.3.7.1 Feeding of labelled L-leucine-5,5,5-D3 
 
Figure S1: A: Isotopic peak pattern of the highly abundant [M+H]+ signals for cystomanamide A 
(609 m/z) prove incorporation of labeled L-leucine in MCy9118. The observed mass shifts fit to the 
heavy isotopes that were incorporated. B: Location of the deuterium label in the fed leucine (*) and 
likely incorporation pattern of leucine skeleton into the fatty acid moiety of cystomanamide A 
(bold lines). 
2.3.8 Gene disruption in MCy9118 via single crossover homologous recombination 
A homologous fragment of each target gene with a size between 975 and 1222 bp was 
amplified from genomic DNA using the respective oligonucleotides that additionally 
inserted stop codons on each side of the fragment. The fragment was ligated into the 
vector pCR®II-TOPO®, resulting in the respective pTOPO derivative for gene disruption. 
The plasmids were transformed into E. coli strain SCS110 for amplification of the plasmid 
without Dam or Dcm methylation. Clones containing the plasmid were selected on LB-
Agar (low salt) supplemented with 50 mg/L Kanamycin-sulfate (Kan) at 37°C. The 
plasmid was recovered from the strain by the alkaline lysis method (Qiagen MiniPrep 
Kit), and after restriction analysis it was introduced into MCy9118 by electroporation (650 
V, 400 ). Mutant clones of MCy9118 were selected on M-Agar (1.5% agar) containing 50 
mg/L Kan. Single clones were used to inoculate liquid medium (M medium + 50 mg/L 
Kan) for secondary metabolite analysis and isolation of genomic DNA for genetic 
verification by PCR. To genetically verify the mutants, two PCR reactions were performed 
for each mutant. The first PCR was performed with primers that bind outside of the 
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region of plasmid insertion. A product is only generated if the gene is not disrupted by 
the plasmid backbone so that the mutants should not show a product in contrast to the 
compared wild type. The second PCR was performed with one primer that binds outside 
of the region of plasmid insertion and one that binds the plasmid backbone. A product is 
only generated if the plasmid was inserted in the right position so that the mutants 
should show a product in contrast to the compared wild type were no product is 
expected. Mutants fulfilling both conditions were considered as genetically verified. 
Table S2. Deduced functions of ORFs in cystomanamide biosynthesis 
Orf protein similarity source organism 
identity 
[%] 
reference 
1 JmjC domain-containing 
protein 
Nostoc sp. 29 ADL59767 
2 protease / beta-lactamase Streptomyces sviceus ATCC 2908
3 
36 WP_007382053 
3 beta-lactamase Nakamurella multipartita DSM 
44233 
33 YP_003202535 
4 beta-lactamase Streptomyces canus 30 WP_020124107 
CtmA putative Aspartate racemase Phaeospirillum molischianum 40 WP_002726614 
CtmB tarine catabolism dioxygenas
e TauD/TfdA 
Nostoc punctiforme ATCC 29133 43 YP_001866803 
CtmC NRPS Paenibacillus alvei 36 WP_005546175 
CtmD amino acid adenylation prote
in 
Clostridium cellulolyticum H10 30 YP_002506645 
5 short-
chain dehydrogenase/reduct
ase 
Methylobacterium extorquens 
AM1 
54 YP_002964386 
6 LysR family transcriptional re
gulator 
Rhizobium etli CFN 42 58 YP_468471 
* Within or in the close neighborhood of the cystomanamide biosynthetic gene cluster, no genes were 
identified showing significant homology to those in charge of the pro-drug activating mechanism described 
by Bode and coworkers (Reimer, D.; Bode, H.B. Nat. Prod. Rep. 2014, 31, 154-9)  
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Table S3. Primers used for amplification and verification of the cystomanamide knockout mutants 
in MCy9118 
 
 
 
 
Figure S2: Principle of homologous recombination and PCR verification used for the Cystobacter 
fuscus MCy9118 mutants 
ctmAKO 
ctmAKOFor  TGATTGATTGAGTCTTCGTCCCCTACAAGCGGATC 
ctmAKORev  TCAATCAATCAAGTCGCCCTTCACCTGGAACC 
Verify_ctmAKO_for GATCATGGAGCAGCAACTGGC 
Verify_ctmAKO_rev CACAGCAGGCGGTAGTACAGC 
orf5KO 
orf5KOFor TGATTGATTGAATGATGCCCGTTCGTGGCGCGTTG 
orf5KORev TCAATCAATCATCACCCGACGTGGTGTTCGCCGTG 
Verify_orf5KO_for CTCCACCGGCTCGTCCATTGG 
Verify_orf5KO_rev GAGTAGGTCGCGTGTTCAGAAACC 
orf2KO 
orf2KOFor TGATTGATTGA GAAGCCTCGCCGGACGAGTCC 
orf2KORev TCAATCAATCAGTTGCTCAACACCACGACCGTCAG 
Verify_orf2KO_for CTCGGAGCCTGTGCCACGACG 
Verify_orf2KO_rev CCCACGTGGTTGCCATCCAGG 
orf4KO 
orf4KOFor TGATTGATTGA AGCTCGCTGGCAGGCCTGCTC 
orf4KORev TCAATCAATCACGTCTCGATGAACGTCTGCTGCTG 
Verify_orf4KO_for CGAACCCATCCATGAACCCTATCG 
Verify_orf4KO_rev CCACGAGGATGTTGTCGGTCG 
pTOPO backbone 
pTOPOin CCTCTAGATGCATGCTCGAGC 
pTOPOout TTGGTACCGAGCTCGGATCC 
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Figure S3. Verification of knockout mutants MCy9118::pLE_ctmAKO, MCy9118::pLE_orf2KO, 
MCy9118::pLE_orf4KO and MCy9118::pLE_orf5KO using PCR  
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Figure S4. Loss of the cystomanamide A production as detected by comparative LC-MS analysis of 
MCy9118 wildtype and mutant strains. An extracted ion chromatogram for the [M+H]+ signal of 
cystomanamide A is shown. A: ctmA knockout mutant; B: orf2 knockout mutant; C: orf5 knockout 
mutant; D: orf4 knockout mutant 
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Figure S5. Loss of the cystomanamide B production as detected by comparative LC-MS analysis of 
MCy9118 wildtype and mutant strains. An extracted ion chromatogram for the [M+H]+ signal of 
cystomanamide A is shown. A: ctmA knockout mutant; B: orf2 knockout mutant; C: orf5 knockout 
mutant; D: orf4 knockout mutant  
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Table S4. NMR spectroscopic data for cystomanamide A (1) (methanol-d4) 
  δCa δHb mult (J in Hz) HMBCc COSYd TOCSYd 
  AMDA         
1 173.2           
2a 37.0 2.68 o 1,3 2b, 3 2b, 3, 4, 5, 6, 7, 8 
2b   2.50 dd (17.0, 9.75) 1, 3, 4 2a, 3 2a, 3, 4, 5, 6, 7, 8 
3 49.8 3.54 m - 2a, 2b, 4 2, 4, 5, 6, 7, 8 
4a 33.8 1.67 m 2, 3, 5, 6 3, 4b, 5 2, 3, 4b, 5, 6, 7, 8 
4b   1.62 m 2, 3, 5 3, 4a, 5 2, 3, 4a, 5, 6, 7, 8 
5 26.2 1.41 dd (7.3, 7.3) 6 4, 6 2, 3, 4, 6, 7, 8, 10, 11 
6 30.5 1.35 o 5, 7, 8 5, 7 2, 3, 4, 5, 7, 8, 9, 10, 11 
7 28.1 1.36 o 5, 6, 8 6, 8 2, 3, 4, 5, 6, 8, 9, 10, 11 
8 40.0 1.21 m 6, 7, 9, 10, 11 7, 9 2, 3, 4, 5, 6, 7, 9, 10, 11 
9 29.0 1.55 m 7, 8, 10, 11 8, 10, 11 5, 6, 7, 8, 10, 11 
10 22.9 0.89 d (6.65) 8, 9, 11 9 7, 8, 9 
11 22.9 0.89 d (6.65) 8, 9, 10 9 7, 8, 9 
  Asn         
1 172.8           
2 51.6 4.77 dd (7.4, 6.3) 1, 3, 4, 1AMDA 3 3 
3a 36.4 2.89 dd (15.8, 6.3) 1, 2, 4 2, 3b 2, 3b 
3b   2.68 o 1, 2, 4 2, 3a 2, 3a 
4 174.9           
  β-OH-Asn         
1 170.1           
2 56.9 4.80 d (3.75) 1, 3, 4, 1Asn 3 3 
3 72.8 4.29 d (3.75) 1, 2, 4 2 2 
4 176.3           
  β-OH-Phe         
1 176.2           
2 61.0 4.49 d (3.25) 
1, 3, 4, 1β-OH-
Asn 
3 3 
3 74.9 5.22 d (3.25) 1, 2, 4, 5, 9 2 2 
4 143.3           
5 127.5 7.34 d (7.45) 3, 7, 9 6, 8 6, 7, 8 
6 128.9 7.28 t (7.45) 4, 8 5, 9, 7 5, 7, 9 
7 128.2 7.20 t (7.45) 5, 9 6, 8 5, 6, 8, 9 
8 128.9 7.28 t (7.45) 4, 6 5, 7, 9 5, 7, 9 
9 127.5 7.34 d (7.45) 3, 5, 7 6, 8 6, 7, 8 
       
aRecorded at 175 MHz; referenced to residual methanol-d4 at δ 49.15 ppm. 
bRecorded at 700 MHz; referenced to residual methanol-d4 at δ 3.31 ppm. 
cProton showing correlation to indicated carbon. 
dProton showing correlation to indicated proton. 
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Table S5. NMR spectroscopic data for cystomanamide B (2) (methanol-d4) 
  δCa δHb mult (J in Hz) HMBCc COSYd TOCSYd 
  AMDA         
1 172.6           
2a 37.3 2.70 dd (16.5, 3.7) 1, 3, 4 2b, 3 2b, 3, 4, 5, 6, 7 
2b   2.54 dd (16.5, 9.2) 1, 3, 4 2a, 3 2a, 3, 4, 5, 6, 7 
3 50.1 3.52 m 2, 4 2, 4 2, 4, 5, 6, 7 
4a 33.8 1.66 m 2, 3, 5, 6 3, 5 2, 3, 4b, 5, 6, 7, 8 
4b   1.62 m 2, 3, 5, 6 3, 5 2, 3, 4a, 5, 6, 7, 8 
5 26.3 1.40 overlap 4, 6 4, 6 2, 3, 4, 6, 7, 8, 10, 11 
6 30.6 1.33 overlap 4, 5, 7, 8 5, 7 2, 3, 4, 5, 7, 8, 9, 10, 
11 
7 28.2 1.34 overlap 6, 8, 9 6, 8 2, 3, 4, 5, 6, 8, 9, 10, 
11 
8 40.0 1.20 m 6, 7, 9, 10, 11 7, 9 4, 5, 6, 7, 9, 10, 11 
9 29.0 1.53 m 7, 8, 10, 11 8, 10, 11 6, 7, 8, 10, 11 
10 22.9 0.89 d (6.6) 8, 9, 11 9 5, 6, 7, 8, 9 
11 22.9 0.89 d (6.6) 8, 9, 10 9 5, 6, 7, 8, 9 
  Asn         
1 173.0           
2 52.1 4.72 dd (7.6, 5.8) 1, 3, 4, 1AMDA 3 3 
3a 37.0 2.80 dd (15.8, 7.6) 1, 2, 4 2, 3b 2, 3b 
3b   2.76 dd (15.8, 5.8) 1, 2, 4 2, 3a 2, 3a 
4 174.5           
  β-OH-Asn         
1 170.6           
2 57.2 4.77 d (4.2) 1, 4, 1Asn 3 3 
3 72.7 4.30 d (4.2) 1, 2, 4 2 2 
4 176.0           
  β-OH-Phe         
1 171.0           
2 60.1 4.75 d (3.6) 1, 3, 4, 1β-OH-Asn 3 3 
3 74.3 5.26 d (3.6) 1, 2, 4, 5, 9 2 2 
4 141.5           
5 127.5 7.35 d (7.5) 3, 7, 9 6, 8 6, 7, 8 
6 129.3 7.31 t (7.5) 4, 5, 8, 9 5, 7, 9 5, 7, 9 
7 128.9 7.24 t (7.3) 5, 9 6, 8 5, 6, 8, 9 
8 129.3 7.31 t (7.5) 4, 5, 6, 9 5, 7, 9 5, 7, 9 
9 127.5 7.35 d (7.5) 3, 5, 7 6, 8 6, 7, 8 
  GA         
1 172.2           
2 71.0 4.24 dd (6.0, 4.0) 1, 3a, 3b 3 3 
3a 67.9 4.32 dd (11.1, 4.0) 1, 1β-OH-Phe 2, 3b 2, 3b 
3b   4.16 dd (11.1, 6.0) 1, 1β-OH-Phe 2, 3a 2, 3a 
  Tyr         
1 177.5           
2 57.2 4.43 dd (7.5, 5.5) 1, 3a, 3b, 4, 1GA 3 3 
3a 38.2 3.12 dd (13.8, 5.5) 1, 2, 4, 5 2, 3b 2, 3b 
3b   2.97 dd (13.8, 7.5) 1, 2, 4, 5 2, 3a 2, 3a 
4 129.5           
5/9 131.4 7.05 d (8.4) 6, 8 6, 8 6, 8 
6/8 116.1 6.68 d (8.4) 5, 9 5, 9 5, 9 
7 156.6           
       aRecorded at 175 MHz; referenced to residual methanol-d4 at δ 49.15 ppm. 
bRecorded at 700 MHz; referenced to residual methanol-d4 at δ 3.31 ppm. 
cCarbon showing correlation to indicated proton. 
cProton showing correlation to indicated proton. 
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Table S6. NMR spectroscopic data for cystomanamide C (3) (methanol-d4) 
  δCa δHb mult (J in Hz) HMBCc TOCSYd 
ROES
Yd 
  AMDA         
1 173.4           
2a 34.3 2.71 o 1, 3 2b, 3, 4, 5, 6, 7, 8   
2b   2.60 dd (17.0, 9.0) 1, 3 2a, 3, 4, 5, 6, 7, 8   
3 57.1 3.59 m   2, 4, 5, 6, 7, 8 1Fru 
4a 31.2 1.77 m   2, 3, 4b, 5, 6, 7, 8 1Fru 
4b   1.62 m   2, 3, 4a, 5, 6, 7, 8 1Fru 
5a 26.4 1.43 m 6 2, 3, 4, 5b, 8, 9, 10, 11   
5b   1.35 o 6 2, 3, 4, 5a, 8, 9, 10, 11   
6 30.7 1.35 o 5, 7, 8 2, 3, 4, 8, 9, 10, 11   
7 28.3 1.35 o 5, 6, 8 2, 3, 4, 8, 9, 10, 11   
8 40.0 1.20 m 6, 7, 9, 10, 11 3, 4, 5, 6, 7, 9, 10, 11   
9 29.1 1.53 m 7, 8, 10, 11 7, 8, 10, 11   
10 22.9 0.89 d (6.5) 8, 9 7, 8, 9   
11 22.9 0.89 d (6.5) 8, 9 7, 8, 9   
  Asn         
1 172.6           
2 51.7 4.75 dd (7.5, 6.5) 1, 3, 4, 1AMDA 3   
3a 36.5 2.87 dd (15.9, 6.5) 1, 2, 4 2, 3b   
3b   2.72 o 1, 2, 4 2, 3a   
4 174.7           
  β-OH-Asn         
1 169.9           
2 56.8 4.82 d (3.5) 1, 3, 4, 1Asn 3   
3 72.8 4.24 d (3.5) 1, 2, 4 2   
4 176.4           
  β-OH-Phe         
1 176.3           
2 60.9 4.51 d (3.0) 
1, 3, 4, 1β-OH-
Asn 
3   
3 74.8 5.25 d (3.0) 1, 4, 5, 9 2   
4 142.9           
5 127.4 7.33 d (7.5) 3, 7, 9 6, 7, 8   
6 128.9 7.28 t (7.5) 4, 5, 8, 9 5, 7, 9   
7 128.1 7.20 t (7.5) 5, 9 5, 6, 8, 9   
8 128.9 7.28 t (7.5) 4, 5, 6, 9 5, 7, 9   
9 127.4 7.33 d (7.5) 3, 5, 7 6, 7, 8   
  Fructose         
1 50.8 3.27 s 2, 3, 3AMDA   3AMDA 
2 96.7           
3 71.0 3.74 d (9.6) 2, 4, 5 5 1 
4 71.1 3.80 dd (9.6, 3.2) 3, 5 5 6a 
5 70.8 3.86 broad signal 4, 6 3, 4, 6a, 6b   
6a 65.0 4.02 d (12.6) 2, 5 5, 6b   
6b   3.69 d (12.6, 1.6) 2, 4, 5 5, 6a   
       
aRecorded at 175 MHz; referenced to residual methanol-d4 at δ 49.15 ppm. 
bRecorded at 700 MHz; referenced to residual methanol-d4 at δ 3.31 ppm. 
cCarbon showing correlation to indicated proton. 
cProton showing correlation to indicated proton. 
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Table S7. NMR spectroscopic data for cystomanamide D (4) (methanol-d4) 
  δCa δHb mult (J, Hz)      
  AMDA       
1 173.4          
2a 36.4 2.86 o      
2b   2.64 o      
3 56.8 3.49 m      
4a 31.2 1.71 m      
4b   1.54        
5 26.3 1.39 m      
6 30.7 1.35 o      
7 28.3 1.35 o      
8 40.0 1.21 m      
9 29.1 1.54 m      
10 23.0 0.89 d (6.7)      
11 23.0 0.89 d (6.7)      
  Asn       
1 172.5          
2 51.5 4.78 o      
3a 36.5 2.83 m      
3b   2.64 m      
4 174.6          
  β-OH-Asn       
1 169.6          
2 57.4 4.86 o      
3 73.0 4.34 d (3.5)      
4 176.3          
  Phe       
1 177.3          
2 57.2 4.40 m      
3a 38.7 3.15 m      
3b   3.00 dd (13.1, 6.1)      
4 139.0          
5 130.8 7.17 d (7.5)      
6 129.2 7.23 t (7.5)      
7 127.3 7.16 o      
8 129.2 7.23 t (7.5)      
9 130.8 7.17 d (7.5)      
  Fructose       
1 50.2 3.29 o      
2 96.8          
3 71.7 3.71 d (9.8)          
4 71.2 3.80 dd (9.8, 3.2)          
5 70.1 3.86 broad signal          
6a 65.2 4.02 d (12.5)          
6b   3.68 dd (12.5, 2.6)          
         
aRecorded at 175 MHz; referenced to residual methanol-d4 at δ 49.15 ppm. 
bRecorded at 700 MHz; referenced to residual methanol-d4 at δ 3.31 ppm. 
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1H NMR spectrum of cystomanamide A (1) in methanol-d4 
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HSQC spectrum of cystomanamide A (1) in methanol d4 
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 HMBC spectrum of cystomanamide A (1) in methanol-d4 
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 DQF-COSY spectrum of cystomanamide A (1) in methanol-d4 
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 2D-TOCSY spectrum of cystomanamide A (1) in methanol-d4 
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13C spectrum of cystomanamide A (1) in methanol-d4 
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 1H NMR spectrum of cystomanamide B (2) in methanol-d4 
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HSQC spectrum of cystomanamide B (2) in methanol-d4 
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HMBC spectrum of cystomanamide B (2) in methanol-d4 
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DQF-COSY spectrum of cystomanamide B (2) in methanol-d4 
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2D-TOCSY spectrum of cystomanamide B (2) in methanol-d4  
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1H NMR spectrum of cystomanamide C (3) in methanol-d4 
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HSQC spectrum of cystomanamide C (3) in methanol-d4 
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HMBC spectrum of cystomanamide C (3) in methanol-d4 
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2D-TOCSY spectrum of cystomanamide C (3) in methanol-d4 
            Cystomanamides   79 
 
  
ROESY spectrum of cystomanamide C (3) in methanol-d4 
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1H NMR spectrum of cystomanamide D (4) in methanol-d4 
            Cystomanamides   81 
 
  
 HSQC spectrum of cystomanamide D (4) in methanol-d4 
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 HMBC spectrum of cystomanamide D (4) in methanol-d4 
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DQF-COSY spectrum of cystomanamide D (4) in methanol-d4 
            Cystomanamides   84 
 
  
 2D-TOCSY spectrum of cystomanamide D (4) in methanol-d4 
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3 Macyranones 
3.1 Abstract 
In our screening efforts to identify unique scaffolds from myxobacteria for the drug 
discovery process, we used LC-SPE-NMR-MS techniques to isolate six linear peptides, 
termed macyranone A – F, from Cystobacter fuscus MCy9118. The macyranones are 
characterized by a rare 2-methylmalonamide moiety and an a-amino ketone fragment 
including an α’,β’-epoxyketone in macyranone A. Gene disruption experiments allowed to 
confirm the biosynthetic gene cluster of the macyranones as PKS/NRPS hybrid. Detailed 
in silico and phylogenetic analysis unraveled that the biosynthesis involves two 
conspicuous amide bond formations accomplished by an amidotransferase and a unique 
condensation domain. The gene cluster provides further insights into the formation of the 
powerful epoxyketone residue involving an acyl-CoA dehydrogenase and an 
unconventional free-standing thioesterase. Macyranone A exhibits a potent inhibitory 
effect against the parasites Trypanosoma brucei rhodesiense and Leishmania donovani with 
IC50 values of 1.55 and 0.22 µM, respectively. Unlike other epoxyketones, macyranone A 
exhibits low cytotoxicity against mammalian and cancer cell lines leaving a potential 
therapeutic window open for development as anti-parasitic agent. Macyranone A was 
found to inhibit the chymotrypsin-like activity of the yeast 20S proteasome with an IC50 of 
5.9 nM and the human constitutive proteasome and immunoproteasome with IC50 of 
21 nM and 15 nM, respectively. The β5 subunit of the 20S proteasome was characterized 
as target by X-ray crystallography revealing an irreversible binding mode similar to the 
natural product epoxomicin. The presence of the methylmalonamide residue facilitates 
the stabilization of macyranone A with the active β5 subunit of the proteasome. 
3.2 Introduction 
The proteasome aroused the interest as therapeutic target because of its involvement in 
many cellular processes like cell cycle control, transcriptional regulation and apoptosis.1 
Up to date, two proteasome inhibitors have been approved by the FDA for the treatment 
of blood cancers such as multiple myeloma and mantle cell lymphoma: the peptide 
boronate bortezomib and the peptidic epoxyketone carfilzomib. Unlike bortezomib, 
which belongs to the first class of synthetic proteasome inhibitors, carfilzomib directly 
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emerged from the natural product epoxomicin.2,3 Another promising drug candidate with 
natural origin is salinosporamide A which was isolated from the marine actinomycete 
Salinispora tropica.4 Moreover, the evaluation of proteasome type specific ligands gave rise 
to alternative strategies to treat chronic inflammation disorders like rheumatoid arthritis 
and multiple sclerosis,5 as well as infectious diseases including malaria6 and human 
sleeping sickness7. The common target of all these compounds is the 20S core particle of 
the proteasome, which is formed by two outer α-rings and two inner β-rings that are 
composed of seven α- and β-subunits, respectively. The two β-rings form a barrel-like 
architecture in which the substrate proteins are cleaved to smaller peptide fragments by 
the catalytically active subunits β1, β2 and β5.1 Although these subunits all share an N-
terminal threonine (Thr1) as active site nucleophile, β1, β2, and β5 differ in their substrate 
specificity for cleavage after acidic, basic, and hydrophobic residues, hence being 
attributed to caspase-like (C-L), trypsin-like (T-L), and chymotrypsin-like (CT-L) activity, 
respectively.8,9 Currently, proteasome inhibitors bearing an α’,β’-epoxyketone 
pharmacophore represent the benchmark for specific proteasome blockage by exploiting 
both nucleophiles, Thr1O and Thr1N. Their inhibitory mechanism results in the 
irreversible formation of a morpholine ring, thereby discriminating against other serine-, 
cysteine- or aspartate proteases.10 Up to date, epoxyketones have mainly been isolated 
from actinobacteria3,11–13 and with the recent discovery of the carmaphycins14,15 also from 
cyanobacteria. The biosynthetic gene clusters of the natural peptidyl-epoxyketones 
eponemycin (Epn) and epoxomicin (Epx) were characterized only recently and gave the 
first insights into the biosynthesis of the epoxyketone warhead.16 Herein, we report the 
first isolation of a new epoxyketone proteasome inhibitor, termed macyranone A (1), 
together with five structural analogues (2-6) from myxobacteria. Since the discovery of 
the first antibiotic myxothiazol17 from myxobacteria in 1980, they have become famous for 
their capability to produce a wide range of secondary metabolites. These gliding bacteria 
have proven to be a rich source of structurally intriguing and bioactive natural products,18 
many of which originate from mixed polyketide-nonribosomal peptide biosynthetic 
pathways.19 Their underlying biosynthetic machineries are termed non-ribosomal peptide 
synthases (NRPSs) and polyketide synthetases (PKSs) and represent large multimodular 
enzymes in which each module is responsible for the selection, activation and 
incorporation of one building block. Such building blocks are usually simple activated 
short chain dicarboxylic acids such as malonyl-CoA or natural as well as non-natural 
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amino acids used to generate a wide range of structurally complex and diverse natural 
products.  
In the search for new natural products from myxobacteria, our focus lies on the 
identification of new scaffolds in a structure-guided isolation approach. We have been 
applying LC-SPE-NMR to screen crude extracts for distinct structural elements. Using this 
approach, we recently isolated a number of new natural products bearing unusual 
scaffolds including the jahnellamides20, the hyalachelins21 and the cystomanamides.22 
3.3 Results and Discussion 
In the course of metabolic profiling of Cystobacter fuscus MCy9118 using the NMR 
screening approach based on structural features, an unknown compound family was 
detected together with the previously reported cystomanamides and the known 
antibiotics althiomycin, roimatacene and myxochelin A and B.22 The small molecules, 
termed macyranones, were isolated from a large scale shake flask cultivation of the 
myxobacterial strain using fractionation via size-exclusion chromatography in 
combination with reversed-phase HPLC for purification of the compounds. Macyranone 
A was the most abundant derivative with a yield of 5.2 mg isolated from 10 L cultivation 
volume. 
3.3.1 Structure elucidation 
HRESIMS of macyranone A displayed an ion peak at m/z 607.2987 [M+H]+ (calcd for 
C29H43N4O10, 607.2974, Δ = 1.97 ppm), consistent with the molecular formula C29H42N4O10 
containing eleven double-bond equivalents (DBE). The 1H NMR spectrum of 1 in 
methanol-d4 exhibited signals characteristic of a peptide including four α-proton signals 
at δ 4.68 (1H, dd, J = 9.0, 4.8 Hz), 4.34 (1H, d, J = 4.0 Hz)  4.37 (1H, d, J = 6.2 Hz) and 4.50 
(1H, dd, J = 10.4, 4.0 Hz) along with five methyl signals at δ 0.92 (3H, d, J = 6.5 Hz), 0.96 
(3H, d, J = 6.6 Hz), 1.16 (3H, d, J = 6.4 Hz), 1.20 (3H, d, J = 6.4 Hz), and 1.26 (3H, d, J = 7.2 
Hz) (see Table S1). Additionally, a downfield pair of triplets at δ 7.28 (2H, t, J = 7.5 Hz) 
and 7.21 (1H, t, J = 7.5 Hz), and a doublet at δ 7.23 (2H, d, J = 7.5 Hz) characteristic of a 
phenyl group were observed. The HSQC spectrum revealed the presence of two methines 
(δC-4ekLeu 25.8, δH-4ekLeu 1.72 and δC-1’ekLeu 52.7, δH-1’ekLeu 3.63), two oxygenated methines (δC-
3Thr 68.1, δH-3Thr 4.17, δC-3aThr 68.6, δH-aThr 4.04) and three methylene groups (δC-2’ekLeu 47.5, δH-
2’ekLeu 3.02/2.98, δC-3ekLeu 39.6, δH-3ekLeu 1.55/1.50 and δC-3Phe 38.2, δH-3Phe 3.26/2.98). A 
detailed analysis of the 2D NMR data obtained from HSQC, HMBC and DQF-COSY 
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experiments established the presence of phenylalanine, two threonine residues, a leucine 
derived epoxyketone residue (ekLeu) and a 2-methylmalonamide residue (Mma). The 
latter was identified by a COSY correlation from the methine proton at δ 3.33 (H-2Mma) to 
methyl protons at δ 1.26 (Me-4Mma) and HMBC correlations from the methine proton at δ 
3.33 (H-2Mma) to the carbon resonances at δ 173.2 (C-1Mma) and 173.3 (C-3Mma). The 
structure of the remaining C8H14NO2 was deduced as follows. A sequential spin system 
starting from the α-proton at δ 4.50 (H-2ekLeu), and followed by two methylene protons at 
δ 1.55/1.50 (H-3ekLeu), the methine proton at δ 1.72 (H-4ekLeu) and two methyl groups at δ 
0.92 and 0.96 (Me-5ekLeu and Me-6ekLeu), which are typical signals for a leucine residue, 
were deduced from TOCSY and COSY spectra. However, an HMBC correlation from H-
2ekLeu to the ketone resonance at δ 207.7 was indicative of a modified leucine residue. 
Indeed, HMBC correlations from H-3ekLeu and the methylene protons at δ 3.02/2.98 (H-
2’ekLeu) to the ketone resonance as well as from the methine at δ 3.63 (H-1’ekLeu) to the α-
-2ekLeu), and a COSY correlation between H-1’ekLeu and H-2’ekLeu clearly 
identified the presence of a leucine derived α’,β’-epoxyketone. The complete sequence was 
established as Phe-Mma-Thr-aThr-ekLeu through HMBC correlations between α-protons 
to carbonyl carbons of adjacent residues (Figure S1). In addition, the composition of 1 was 
supported by ESI-MS/MS measurements. The MS2 spectrum of the major ion peak at m/z 
607 displayed ions at m/z 432 [M+H-ekLeu-H2O]+, m/z 331 [M+H-aThr-ekLeu-H2O]+, and 
m/z 230 [M+H-Thr-aThr-ekLeu-H2O]+. Thus, the fragmentation patterns were in 
agreement with the structure of 1 determined by NMR. 
Macyranone A was shown to be instable in buffered aqueous systems at room 
temperature. An intramolecular rearrangement of the epoxide ring results in the furanone 
ring that is found in macyranone B (2). Besides macyranone A and B, four additional 
analogues (3-6) were isolated from the crude extract (Figure 3.1A). 
The molecular formula of macyranone C (3) was established to be C29H44N4O9 (m/z 
593.3181 [M+H]+). Its NMR data (Table S2) closely resemble to that of 1, except for the 
replacement of signal belonging to the epoxide group for an ethyl group (etLeu) (δC-2’etLeu 
8.4, δH-2’etLeu 0.99; δC-1’etLeu 33.7, δH-1’etLeu 2.56). Macyranone D and E (4 and 5) turned out to 
be composed of C29H40N6O9 (m/z 617.2938 [M+H]+) and C34H43N5O9 (m/z 666.3121 
[M+H]+), respectively. The NMR data (Table S2) revealed that their amino acid sequence 
is identical to that of 3, only differing by the occurrence of histidine in 4 and tryptophan 
in 5 instead of leucine. Macyranone F displays an ion peak at m/z 652.2933 [M+H]+ 
  
Figure 3.1. A) Structures of the macyranones A - F. B) Structures of other proteasome inhibitors. 
           Macyranones 94 
 
(corresponding to a molecular formula C33H41N5O9) which lacks 14 Da compared to 5. In 
fact, a threonine residue is replaced by a serine residue as revealed by NMR data (Table 
S2). 
The absolute configurations of the amino acid residues in the natural products were 
determined by MS detected chromatographic analysis of the L- and D-FDLA (1-fluoro-2,4-
dinitro-phenyl-5-L/D-leucinamide) derivatives of the acid hydrolyzate of macyranone A-
F (Table S3).23 It was found that all the amino acid residues present in the macyranones 
possess L-configuration. Moreover, LC-MS analysis indicated the presence of L-threonine 
and L-allo-threonine in compounds 1-5. The absolute configurations of the two threonine 
residues were determined in 5 by J based configuration analysis.24 A large coupling 
constant of 3JH-H = 6.5 Hz indicated an anti-orientation between H-2aThr and H-3aThr. 
Additionally, a ROESY spectrum recorded in DMSO-d6 displayed a correlation from 
NHaThr to Me-4aThr (see Figure S2). Taken together, these data reveal an erythro 
configuration for C-2aThr and C-3aThr thereby establishing the absolute configuration of Thr 
and aThr as L-threonine, and aThr as L-allo-threonine. Identical configurations for 1-5 
were assumed at comparable chiral centers based on the similarities of their structures 
and NMR data. 
The R configuration of the epoxyketone warhead was deduced via the co-crystal structure 
of macyranone A in complex with the 20S proteasome as described for epoxomicin10 
which is illustrated by the structural superposition in Figure 3.4. For macyranone B, we 
observe that the conversion of 1 is not stereospecific since it yields a racemic mixture of 2. 
Further, the 2-methylmalonamide residue present in all macyranones undergoes a fast 
proton exchange which prevented the assignment of its configuration. 
3.3.2 Identification of the myn biosynthetic gene cluster 
The chemical structures of the macyranones suggest that the compounds are products of a 
polyketide synthase (PKS) and non-ribosomal peptide synthetase (NRPS) hybrid. The 
building blocks of the macyranones are expected to include L-phenylalanine, 
methylmalonyl-CoA, L-threonine, L-allo-threonine or L-serine, a variable amino acid 
(leucine, histidine or tryptophan), and a malonyl-CoA unit. Using the bioinformatic 
prediction tool antiSMASH 2.0,25 a candidate PKS/NRPS biosynthetic gene cluster (myn) 
was identified. The predicted gene cluster consists of eight open reading frames (ORFs) 
with an overall GC content of 70.0%. Analysis of the catalytic domains led to the 
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prediction of three NRPS modules and one PKS module (Figure 3.2). The adenylation 
domain specificity in the three NRPS modules matched the distinct pattern of building 
blocks for the core amino acid motif Thr-Thr-Leu (Table S5). Genes that did not yield a 
prediction for PKS or NRPS domains were analyzed via the BLAST algorithm26 (blastx) 
against the non-redundant NCBI database (Table 3.1, Table S4). 
Feeding experiments with labeled sodium propionate [1-13C] and sodium acetate [13C2] 
depicted the incorporation of methylmalonyl-CoA and malonyl-CoA, respectively. 
Incorporation of leucine-d3 confirmed the biosynthetic origin of the ekLeu residue as 
leucine-derived (Figure S3). 
Intriguingly, the identified building blocks do not exhibit the typical composition 
reflecting a sequential N- to C-terminal biosynthesis. Based on the arrangement and 
presence of modules responsible for the incorporation of building blocks, it seems more 
likely that the assembly line starts with threonine. Subsequent attachment of 
phenylalanine and methylmalonyl-CoA occur via an alternative route. MynA shows 
sequence similarity to a family of asparagine synthetases with the closest similarity to 
PdmN from the pradimicin pathway27 (41.6 % identity), to RubR from the rubromycin 
pathway (40.3 % identity), and to FdmV from the fredericamycin pathway28 (39.5 % 
identity). Alignment of the three enzymes to the typical asparagine synthetase B-like 
amide synthetase (AS B) from E. coli (20.5 % identity) shows that all mentioned enzymes 
contain the conserved domains present in AS B: the N-terminal glutaminase domain and 
the C-terminal amide synthetase domain (Figure S4).29 The glutaminase domain is 
responsible for the hydrolysis of L-Glu to supply a free ammonia group and the amide 
synthase domain catalyzes the conversion of aspartate to asparagine via a β-aspartyl-
AMP intermediate.30,31 For FdmV, it was proven that it catalyzes lactam ring formation 
with l-Glu, l-Asn or free NH3 as nitrogen source.28 All class II glutamine 
amidotransferases contain a conserved N-terminal cysteine residue (Cys2) that was 
shown to act as active-site nucleophile for the hydrolysis of glutamine to glutamate and 
ammonia.32 This residue is retained in AS B and FdmV but is mutated to serine in MynA, 
PdmN, and RubR. The mutation leads to a loss of the glutaminase activity in the three 
enzymes whereas the active site residues responsible for the coordination of the AMP 
intermediate are preserved. RubR could not be assigned to a function but PdmN was 
suspected to be responsible for transferring an amino acid into the polyketide 
intermediate of pradimicin.27 Therefore, the amide synthetase activity seems to be 
  
Figure 3.2. Gene cluster of the macyranones in Cystobacter fuscus MCy9118 and the deduced biosynthetic pathway of 1. 
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retained in MynA and PdmN by using other substrates as nitrogen donor (L-Phe and D-
Ala, respectively). Consequently, MynA could be accountable for amide bond formation 
between the methylmalonic acid residue and phenylalanine via an AMP intermediate 
with phenylalanine acting as amino donor. The first adenylation domain found in the 
identified myn biosynthetic gene cluster is a stand-alone adenylation domain with 
threonine substrate specificity predicted for mynB. The coupling of the methylmalonate-
phenylalanine and the first threonine could be catalyzed by the condensation domain in 
the first module of the peptide synthetase as discussed for lipopeptide biosynthesis.33 
Phylogenetic analysis indeed demonstrated a highly unusual nature of this C domain 
since it does not group with other known types like LCL type, DCL type, starter, hybrid, 
cyclization, epimerization or dual function condensation domains (Figure S5). 
Table 3.1. Deduced functions of open reading frames in the macyranone biosynthetic gene cluster 
Protein Proposed function 
MynA amidotransferase 
MynB stand-alone A1Thr domain  
MynC acyl-CoA dehydrogenase 
MynD NRPS (C-PCP, C-A2Thr-PCP, C-A3Leu-PCP) 
MynE transporter 
MynF stand-alone A4His domain 
MynG PKS (KS-AT-ACP) 
MynH thioesterase type II 
  
Alternatively, the stand-alone adenylation domain encoded by mynB is a possible 
candidate for the amide bond formation as shown for orf19, which encodes an amidating 
stand-alone A domain in streptothricin biosynthesis.34 Comparison of the adenylation 
domains did not provide valuable information about the possible function of MynB.  
The biosynthesis continues with MynD. Besides the condensation domain and the PCP 
from the first module, the protein contains two additional modules where the adenylation 
domains show specificity for threonine and leucine, respectively. These two modules 
correspond to the sequence of the amino acid residues in the main product macyranone 
A. MynF encodes a second stand-alone adenylation domain with histidine substrate 
specificity (Table S5). 
Since some of the macyranones contain a leucine residue (macyranone A to C) and some 
contain a histidine (D) or tryptophan residue (E and F), MynF might act as an alternative 
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adenylation domain for module 3. The PKS which is responsible for the attachment of the 
C terminal malonyl-CoA unit is localized on mynG. Although active site analysis of the 
respective AT domain predicted the incorporation of an unusual substrate (Table S6), 
feeding experiments with sodium acetate [13C2] indicated the incorporation of malonyl-
CoA (Figure S3). mynE seems to encode a transporter whereas mynH encodes a 
thioesterase type II. The latter protein exhibits some unusual features as revealed by 
phylogenetic analysis (Figure S7); in general, type I thioesterase domains remove the final 
product through hydrolysis and are usually integrated into the final module of the 
assembly line complex, whereas type II thioesterases are discrete proteins that can remove 
intermediates from any module in the complex. The TE shows similarity to a group of 
thioesterase domains characterized on the basis of the ajudazol TE (AjuTE) by Buntin et 
al. in 2010.35 The AjuTE is integrated into a PKS module but phylogenetic analysis 
associated it with type II thioesterases. Therefore, the authors suggested that the TE was 
once a stand-alone type II TE domain, but was fused genetically to the end of the ajudazol 
assembly line and acts there as hydrolytic type I TE. The AjuTE is expected to be involved 
in isochromanone ring formation. As a consequence of this similarity, we believe that the 
type II TE domain present at the terminus of the myn gene cluster plays a crucial role in 
the release of the substrate from the assembly line and therefore in the formation of the 
epoxyketone unit. In comparison to the biosynthesis of the epoxyketones epoxomicin and 
eponemycin (12)16, only eponemycin biosynthesis involves a similar free-standing TE 
(EpnB) that also shows 37.5 % similarity to MynH on the protein level. In contrast to the 
myn cluster, both clusters contain an integrated type I TE domain downstream of the final 
PKS module. Comparing the recently identified biosynthetic gene clusters of epoxomicin 
(epx) and eponemycin (epn) to the identified cluster of macyranone, it is striking that all 
three clusters encode an acyl-CoA dehydrogenase (mynC, epxF, and epnF), indicating a 
major role for this protein in the biosynthesis of the epoxyketone warhead. For 
epoxomicin and eponemycin, the authors suggested16 a release of the intermediates as 
carboxylic acids by the C-terminal thioesterase domain with subsequent reduction and 
epoxidation accomplished by the acyl-CoA dehydrogenase (ACAD EpxF/EpnF) and a 
cytochrome P450 (CYP) monooxygenase (EpxC/EpnI), respectively. Alternatively, a 
mechanism that involves a putative C-methyltransferase domain found in both clusters 
with subsequent decarboxylation that initiates the epoxide formation by the ACAD and 
CYP P450 was taken into consideration. However, in contrast to the epx and epn clusters, 
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the gene cluster of macyranone does not contain a gene that encodes for a CYP P450 
enzyme. Additionally, no C-methyltransferase domain was identified in the final PKS 
module (as reasoned by the unsubstituted epoxide ring of 1) compared to epoxomicin and 
eponemycin.  
Based on our findings, we take another mechanism for epoxyketone formation into 
consideration: MynC as well as EpxF and EpnF resemble very-long chain acyl-CoA 
dehydrogenases (VLCAD) isolated from mammalian sources. VLCAD are responsible for 
α,β-dehydrogenation of long-chain fatty acid acyl-CoA conjugates.36 Members of the 
ACAD superfamily belong to the flavoproteins and were shown to catalyze various redox 
reactions including α,β-dehydrogenation, oxidation of nitroalkanes37 as well as 
desulfurization38. Acyl-CoA dehydrogenases in general act on CoA esters rather than on 
free fatty acids.39 Thus, we suggest as alternative an acyl-carrier-bound mechanism 
involving the acyl-CoA dehydrogenase MynC. A reductive mechanism similar to such 
catalyzed by reductase domains40,41 in combination with simultaneous oxidation of the α-
position of the ketone catalyzed by MynC could lead to a release of the compound as 
epoxyketone. Chain release may be spontaneous or involve the free-standing thioesterase 
MynH resulting in the epoxide (1) and, to a smaller extent, furanone (2) ring formation. 
Full reduction of the product might lead to macyranone C-F. Obviously, formation of the 
epoxyketone requires further analysis by biochemical studies. Figure 3.2 illustrates the 
genetic organization of the macyranone PKS/NRPS hybrid biosynthetic gene cluster as 
determined by in silico analysis including a biosynthetic hypothesis. 
3.3.3 Gene disruption in MCy9118 
To confirm that the identified candidate gene cluster is responsible for macyranone 
production, a single crossover knockout strategy was established. Gene disruption in 
MCy9118 via single crossover homologous recombination was accomplished according to 
a previously described protocol.22 HPLC analysis of the resulting mynA, mynC and mynD 
mutants revealed that inactivation of all three genes abolished the production of the 
macyranones (Figure 3.3). These results confirm that the identified candidate biosynthetic 
gene cluster is indeed responsible for macyranone production. 
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Figure 3.3. Loss of the macyranone A and B production in the MCy9118 knockout mutants 
mynAKO, mynDKO and mynCKO as detected by comparative HPLC-MS analysis of MCy9118 
wildtype and mutant strains. An extracted ion chromatogram for the [M+H]+ signal of 
macyranone A and B is shown. 
3.3.4 Biological activity 
Macyranone A inhibits the CT-L activity of the yeast 20S proteasome with an IC50 of 5.9 
nM. It does not show an effect on the C-L activity whereas it modulates the T-L activity 
with an IC50 of 400 nM. Macyranone B, D, and E did not block any active site up to a 
tested concentration of 10 µM. Next, 1 was tested against the human constitutive 
proteasome (cCP) and immunoproteasome (iCP). Both subunits were simultaneously 
inhibited with an IC50 of 21 nM and 15 nM, respectively. However surprisingly, 
macyranone A does not show the expected high cytotoxicity against mammalian cell lines 
such as the human colon carcinoma HCT-116 cell line, the human leukemia cell lines 
THP-1 and HL-60, and the rat myoblast cell line L-6. Moreover, macyranone A shows a 
potent antiparasitic activity against Trypanosoma brucei rhodesiense, the causative agent of 
the African sleeping sickness and against extracellular grown amastigotes of Leishmania 
donovani causing leishmaniasis (Table 3.2). The activity against L. donovani is lost in the 
intracellular amastigote assay tested up to a concentration of 30 µM. Thus, due to the 
close similarity of the proteasomes in all eukaryotic cells, we expect that the selectivity 
towards the parasitic cells is a transport phenomenon or a metabolism-related 
specificity.42 Macyranone A shows a poor stability in buffered aqueous systems that could 
be an explanation for the discrepancy between in vitro inhibition of the 20S proteasome 
and in vivo activity against eukaryotic cells. 
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Table 3.2: Biological activity of macyranone A and epoxomicin 
Bioactivity assay 
Macyranone A 
IC50 [µM] 
Epoxomicin 
IC50 [µM] 
Constitutive proteasome (Human, 10µg/mL), β5 subunit 0.021  
Immunoproteasome (Human, 10µg/mL), β5 subunit 0.015  
20S Proteasome (Yeast, 0.5 nM), β5 subunit 0.006  
Trypanosoma brucei rhodesiense 1.55  
Leishmania donovani 0.22  
Plasmodium falciparum 41.6  
HCT-116 29.2 0.0028 
THP-1 38.3 0.0116 
HL-60 21.9 0.0042 
L-6 > 100  
3.3.5 Crystal structure of the 20S proteasome:macyranone A complex 
To characterize the binding mode of macyranone A, we determined the crystal structure 
of the yeast 20S proteasome in complex with macyranone A (2.8 Å resolution, Rfree = 
21.9 %, PDB ID 5AHJ). Consistent with the proteasome:epoxomicin complex structure, 
macyranone A binds to the catalytically active Thr1 of all active subunits β1, β2 and β5 
(Figure 3.4).10 The mode of action comprises the nucleophilic attack of both nucleophiles 
present at the active site, Thr1O and Thr1N, resulting in an irreversible morpholine ring 
adduct formation. Due to the bivalent binding to the N-terminal Thr1, macyranone A 
fulfills the requirement to selectively block the small class of N-terminal threonine 
nucleophile (Ntn) hydrolases, potentially preventing any off-target activity as shown in 
the case of the clinically relevant carfilzomib.43 Furthermore, macyranone A is stabilized 
by antiparallel β-sheet formation of the peptide backbone in the substrate binding channel 
combined with distinct stabilization in the substrate specificity pockets. In this regard, the 
unusual 2-methylmalonamide unit causes a shift at the end of the peptide scaffold, which 
allows the C-terminal phenylalanine to hydrophobically interact with Ala22 of subunit β5 
to achieve further stabilization. Moreover, the X-ray crystallographic studies complement 
the results of the NMR spectroscopic analysis supporting the peptide sequence as well as 
the assigned stereochemistry of macyranone A. 
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Figure 3.4. A: X-ray crystallographic binding analysis of macyranone A bound to the yeast 20S 
proteasome (yCP, PDB ID 5AHJ). B: The 2Fo−Fc electron density map (cyan mesh, contoured at 1) 
shows bound macyranone A (green) at Thr1 (black) and the oxyanion hole formed by G47 (black). 
Hydrogen-bonding of the ligand to subunit β5 (yellow) and subunit β6 (pale orange) is indicated 
by black dashed lines. C: Structural superposition of bound macyranone A (green) and epoxomicin 
(grey) at the Thr1 of subunit β5 of yCP. 
3.4 Conclusions 
The macyranones represent a new family of natural products isolated from myxobacteria. 
Their core structure consists of three amino acid residues, an unprecedented 2-
methylmalonamide moiety, and an α-amino ketone fragment formed by condensation of 
an amino acid and an acetate-derived ethyl unit. In particular, macyranone A bears the 
powerful epoxyketone warhead found in the group of α’,β’-epoxyketones.  
The biosynthesis of the macyranones deviates widely from the textbook logic of 
PKS/NRPS hybrids. During macyranone formation, the amidotransferase and the 
unconventional condensation domain are involved in two conspicuous amide bond 
formations comprising unprecedented biochemical reactions. Additionally, a acetyl-CoA 
dehydrogenase homologue and possibly also the type II thioesterase are involved in the 
formation of the epoxyketone residue representing highly unusual features where in silico 
analysis can currently only provide an idea of the real biosynthetic mechanism. The 
C 
A B 
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identification of the biosynthetic gene cluster, detailed in silico analysis and the 
confirmation of the gene cluster via gene deletion thus set the stage for further detailed 
biochemical studies. 
Moreover, macyranone A shows a potent activity in vitro against the β5 subunit of the 
human constitutive proteasome as well as the immunoproteasome. Additionally, 1 is 
active in vivo against the parasites Trypanosoma brucei rhodesiense and Leishmania donovani. 
With a surprisingly low cytotoxicity to mammalian cell lines, macyranone A exhibits a 
potential therapeutic window in contrast to other proteasome inhibitors that translate 
their 20S proteasome inhibition into high cytotoxicity. Therefore, the highly potent 
natural product may contribute to the development of new anti-parasitic agents for the 
treatment of infectious diseases like the African sleeping sickness. 
X-ray analysis of macyranone A in complex with the yeast 20S proteasome confirms the 
covalent binding mechanism of the epoxyketones at the β5 subunit. Furthermore, the 
unusual 2-methylmalonamide residue was identified to further stabilize the ligand in the 
substrate binding channel allowing a hydrophobic interaction between the C-terminal 
phenylalanine and subunit β5.  
In closing, these results contribute to our understanding of the selective blockage of the 
ubiquitous eukaryotic 20S proteasome and could be of help to the development of new 
anti-parasitic agents. Also, the identification of the biosynthetic gene cluster, detailed in-
silico analysis and the confirmation of the gene cluster via gene deletion set the stage for 
further studies in the formation of the epoxyketone functionality. Finally, the potential 
development of macyranone A as antiparasitic drug provides another example of the 
importance of myxobacteria in drug discovery programs. 
3.5 Experimental Section 
3.5.1 General experimental procedures 
NMR spectra were recorded in methanol-d4 on a Bruker Ascend 700 spectrometer with a 5 
mm TXI cryoprobe (1H at 700 MHz, 13C at 175 MHz) or a Bruker Avance III 500 
spectrometer with a 5 mm TXI cryoprobe (1H at 500 MHz, 13C at 125 MHz). DQFCOSY, 
HOHAHA, HSQC, HMBC, and ROESY experiments were recorded using standard pulse 
programs. HSQC experiments were optimized for 1JC-H = 145 Hz, and HMBC spectra were 
optimized for 2,3JC-H = 6 Hz. The samples were dissolved in methanol-d4 and the chemical 
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shifts of the solvent signals at 3.31 ppm (δH) and 49.15 ppm (δC) were considered as 
internal standard (reference signal). The observed chemical shift (δ) values were given in 
ppm and the coupling constants (J) in Hz. 5mm Shigemi tubes (Shigemi Inc., Allison Park, 
PA 15101, USA) were used to increase sensitivity. A Dionex Ultimate 3000 RSLC system 
was used for LC-HRMS measurements with a Waters BEHC18, 100 x 2.1 mm, 1.7 µm dp 
column. Separation of 2 µl sample was achieved by a linear gradient with (A) H2O + 0.1 % 
FA to (B) ACN + 0.1 % FA at a flow rate of 600 µl/min and 45 °C. The gradient was 
initiated by a 0.5 min isocratic step at 5 % B, followed by an increase to 95% B in 18 min to 
end up with a 2 min step at 95 % B before reequilibration with initial conditions. UV 
spectra were recorded by a DAD in the range from 200 to 600 nm. The LC flow was split 
to 75 µl/min before entering the maXis HR-ToF mass spectrometer (Bruker Daltonics, 
Bremen, Germany) using the standard ESI source. Mass spectra were acquired in centroid 
mode ranging from 150 - 2000 m/z at 2 Hz scan speed.  
3.5.2 Cultivation of strain MCy9118 
The myxobacterial strain Cystobacter fuscus MCy9118 was isolated and cultivated using 
previously reported methods.22 For the production of the macyranones, the preculture 
was used to inoculate 300 ml shake flasks containing 50 mL VY/2S-DY medium (0.4 % 
dry yeast, 0.05 % CaCl2 x 2 H2O, 1.0 % soluble starch, 5 mM HEPES adjusted to pH 7.0 
with 10 N KOH) that was incubated at 30 °C for 8 h. Always 20 mL of the cultures were 
used to inoculate six times 2 L VY/2S-DY medium containing 8 mg/mL Fe-EDTA in 5 L 
shake flasks (shaking rate 160rpm; 30°C). 2 % XAD adsorber resin (Amberlite XAD-7, 
Sigma) was added to the shake flasks on day 2 of the cultivation. The cultures were 
incubated for 7 days. Cultures were harvested by sieving the culture to receive the XAD.  
3.5.3 Isolation procedure 
XAD was washed with ddH2O to remove salts prior to freeze drying. The XAD was 
extracted exhaustively with MeOH to obtain the crude extract. Sephadex fractionation 
was performed using a GE Healthcare SR 25/100 column, sephadex LH 20 was used for 
separation and methanol as mobile phase. The fractions containing the respective 
peptides were combined and the solvent was evaporated. The compounds were 
separated by preparative HPLC. A Waters Xbridge C18, 150x19 mm, 5 µm dp column was 
used and a linear gradient from 5 to 95% B in 30min with (A) H2O + 0.1 % FA and (B) 
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MeOH + 0.1 % FA at a flow rate of 25 mL/min at room temperature. Each injection 
consisted of up to 150 mg of the combined fractions dissolved in 500 μl MeOH. Fractions 
were collected by time in test tubes. The compounds were repurified by semipreparative 
HPLC at 30°C eluting with a linear gradient and column according to the compound 
description and a DAD at 220nm.  
Macyranone A (1): 1H and 13C NMR data, see Table S1; HRESIMS m/z 607.2967 [M+H]+ 
corresponding to a molecular formula C29H42N4O10 (calcd for C29H43N4O10, 607.2974, Δ = 
1.2 ppm) Isolation: Phenomenex Synergi™ 4 μm Fusion-RP 80 Å, LC Column 250 x 10 
mm; tR = 39.5 min; flow rate = 2.5 ml/min; 0-1min 10% B, 1-45min 10-90% B; A: H2O + 
0.1% FA, B: MeOH + 0.1% FA  
Macyranone B (2): 1H and 13C NMR data, see Table S2; HRESIMS m/z 607.2963 [M+H]+ 
corresponding to a molecular formula C29H42N4O10 (calcd for C29H43N4O10, 607.2974, Δ = 
1.8 ppm) Isolation: Jupiter® 4 µm Proteo 90 Å, LC Column 250 x 10 mm; tR = 43.9 min; 
flow rate = 2.5 ml/min; 0-7min 34% B, 7-47min 34-75% B; A: H2O + 0.1% FA, B: MeOH + 
0.1% FA  
Macyranone C (3): 1H and 13C NMR data, see Table S2; HRESIMS m/z 593.3181 [M+H]+ 
corresponding to a molecular formula C29H44N4O9 (calcd for C29H45N4O9, 593.3181, Δ = 0 
ppm) Isolation: Jupiter® 4 µm Proteo 90 Å, LC Column 250 x 10 mm; tR = 25.1 min; flow 
rate = 2.5 ml/min; 0-1min 10% B, 1-45min 10-90% B; A: H2O + 0.1% FA, B: ACN + 0.1% 
FA 
Macyranone D (4): 1H and 13C NMR data, see Table S2; HRESIMS m/z 617.2938 [M+H]+ 
corresponding to a molecular formula C29H40N6O9 (calcd for C29H41N6O9, 617.2930, Δ = 1.3 
ppm) Isolation: Synergi™ 4 µm Polar-RP 80 Å, LC Column 250 x 10 mm; tR = 23.3 min; 
flow rate = 3.5 ml/min; 0-1min 10% B, 1-41min 10-90% B; A: H2O + 0.1% FA, B: MeOH + 
0.1% FA  
Macyranone E (5): 1H and 13C NMR data, see Table S2; HRESIMS m/z 666.3121 [M+H]+ 
corresponding to a molecular formula C34H43N5O9 (calcd for C34H44N5O9, 666.3134, Δ = 2.1 
ppm) Isolation: Jupiter® 4 µm Proteo 90 Å, LC Column 250 x 10 mm; tR = 40.7 min; flow 
rate = 2.5 ml/min; 0-1min 10% B, 1-45min 10-90% B; A: H2O + 0.1% FA, B:ACN + 0.1% FA  
Macyranone F (6): 1H and 13C NMR data, see Table S2; HRESIMS m/z 652.2933 [M+H]+ 
corresponding to a molecular formula C33H41N5O9 (calcd for C33H42N5O9, 652.2977, Δ = 6.7 
ppm) Isolation: Jupiter® 4 µm Proteo 90 Å, LC Column 250 x 10 mm; tR = 39.6 min; flow 
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rate = 2.5 ml/min; 0-1min 10% B, 1-45min 10-90% B; A: H2O + 0.1% FA, B: ACN + 0.1% 
FA  
3.5.4 Advanced Marfey’s method44 
Approximately 0.2 mg of the compound were hydrolyzed with 6 N HCl (0.8 mL) and 
shaken at 90°C for 16 h in Eppendorf tubes. Samples were dried under vacuum and 
dissolved in H2O (100 μL). They were split into two 50 μL aliquots and 1 N NaHCO3 (20 
μL) and 1% 1-fluoro-2,4-dinitrophenyl-5-leucine-amide (L-FDLA or D-FDLA solution in 
acetone, 100 μL) were added respectively. The mixtures were heated to 40°C for 40 min, 
cooled down to RT and the reaction was quenched by addition of 2 N HCl (20 μL). 
Solvents were evaporated under nitrogen and residues were redissolved in 1 mL CH3CN 
and subsequently analyzed by LCMS. All measurements were performed on a Dionex 
Ultimate 3000 RSLC system using a Waters BEH C18, 100 x 2.1 mm, 1.7 μm column by 
injection of 1 μl sample. Separation was achieved by a gradient using (A) H2O + 0.1% FA 
to (B) ACN + 0.1% FA at a flow rate of 550 μl/min and 45 °C. The gradient was as follows: 
starting at 5 % B to increase to 10 % B in 1 min, from 1 to 15 min increase to 35 % B, from 
15 to 22 S5 min increase to 50% B, from 22 to 25 min increase to 80 % B. After a 1 min hold 
at 80 % B the system was reequilibrated with initial conditions for 5 minutes. UV data was 
acquired at 340 nm and MS-detection was performed simultaneously. Coupling the 
HPLC to the MS was supported by an Advion Triversa Nanomate nanoESI system 
attached to a Thermo Fisher Orbitrap. LC flow is split to 500 nl/min before entering the 
ion source. Mass spectra were acquired in centroid mode ranging from 150 to 1000 m/z at 
a resolution of R = 30000. Results can be found in Table S3. 
3.5.5 Sequence analysis 
Routine DNA in silico sequence analysis was carried out using the Geneious® 6.1.6 
software. Annotation of the catalytic domains and characterization of the A domain 
substrate specificity was performed using the tools antiSMASH 2.025, Pfam45, 
NRPSpredictor246, PKS/NRPS Analysis47 and NaPDoS48. 
3.5.6 General procedures for DNA manipulation and PCR 
Chromosomal DNA from MCy9118 was prepared using the Puregene ® Core Kit A 
(Qiagen) according to the manufacturer’s instructions. PCR was carried out using 
Phusion High Fidelity DNA Polymerase (Thermo Scientific) according to the 
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manufacturer’s protocol with addition of 5% DMSO to the reaction mixture. For the 
amplification, conditions were: Initial denaturation step at 98°C for 2 min, denaturation 
for 10 sec at 98°C, annealing for 15 sec at 60 to 70°C according to the primer, extension at 
72°C for 2min (30 cycles) and a final extension step at 72°C for 10 min. PCR products were 
purified via agarose gel electrophoresis and subsequent extraction from the gel using the 
peqGOLD Gel Extraction Kit (Peqlab). Ligation of DNA fragments with sticky ends was 
done using T4 DNA Ligase (Thermo Scientific) according to the manufacturer protocol 
using a 4:1 molar ratio of insert and vector. Restriction digest was done using enzymes 
from Thermo Scientific according to the manufacturer’s protocol and recommendations 
regarding double digest. For pTOPO cloning, the TOPO TA Cloning Kit with pCR® 2.1 
TOPO vector (Invitrogen) was used. Plasmids were introduced into chemically competent 
E. coli strains via heat shock transformation and into C. fuscus MCy9118 via 
electroporation at 650 V and 400 . E. coli Clones containing a plasmid were selected on 
LB agar (1.5% agar) supplemented with 50 mg/L Kanamycin-sulfate (Kan) at 37°C. 
Mutant clones of MCy9118 were selected on M-agar (1.5% agar) containing 50 mg/L Kan. 
3.5.7 Single crossover homologous recombination strategy 
Gene disruption in MCy9118 via single crossover homologous recombination was 
accomplished according to a previously described protocol22. A homologous fragment of 
each target gene with a size around 1 kb was amplified from genomic DNA using the 
respective oligonucleotides listed in Table S7 that additionally inserted stop codons on 
each side of the fragment. The fragment was ligated into the vector pCR®II-TOPO®, 
resulting in the respective pTOPO derivative for gene disruption. The plasmids were 
transformed into E. coli strain SCS110 for amplification of the plasmid without Dam or 
Dcm methylation. The plasmid was recovered from the strain by the alkaline lysis 
method, and after restriction analysis it was introduced into MCy9118 by electroporation. 
Single clones were used to inoculate liquid medium (M medium + 50 mg/L Kan) for 
secondary metabolite analysis and isolation of genomic DNA for genetic verification by 
PCR. Subsequent HPLC analysis of the resulting mynA, mynC and mynD mutants 
revealed that inactivation of the three genes abolished production of the macyranones.  
To genetically verify the mutants, two PCR reactions were performed for each mutant 
(see Figure S8). The first PCR was performed with primers that bind outside of the region 
of plasmid insertion. A product is only generated if the gene is not disrupted by the 
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plasmid back-bone so that the mutants should not show a product in contrast to the 
compared wild type. The second PCR was performed with one primer that binds outside 
of the region of plasmid insertion and one that binds the plasmid backbone. A product is 
only generated if the plasmid was inserted in the right position so that the mutants 
should show a product in contrast to the compared wild type were no product is 
expected. Mutants fulfilling both conditions were considered as genetically verified. 
3.5.8 Activity against Trypanosoma brucei rhodesiense STIB900 
This stock was isolated in 1982 from a human patient in Tanzania and after several mouse 
passages cloned and adapted to axenic culture conditions.49 Minimum Essential Medium 
(50 µl) supplemented with 25 mM HEPES, 1 g/L additional glucose, 1 % MEM non-
essential amino acids (100x), 0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate and 15 % 
heat inactivated horse serum was added to each well of a 96-well microtiter plate. Serial 
drug dilutions of eleven 3-fold dilution steps covering a range from 100 to 0.002 μg/ml 
were prepared. Then 4x103 bloodstream forms of T. b. rhodesiense STIB 900 in 50 µl was 
added to each well and the plate incubated at 37 °C under a 5 % CO2 atmosphere for 70 h. 
10 µl Alamar Blue (resazurin, 12.5 mg in 100 mL double-distilled water) was then added 
to each well and incubation continued for a further 2–4 h.50 Then the plates were read 
with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, 
Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an emission wave 
length of 588 nm. The IC50 values were calculated by linear regression51 from the 
sigmoidal dose inhibition curves using SoftmaxPro software (Molecular Devices 
Cooperation, Sunnyvale, CA, USA). Melarsoprol (Arsobal Sanofi-Aventis, received from 
WHO) is used as control. 
3.5.9 Activity against Leishmania donovani axenic amastigotes 
Amastigotes of L. donovani strain MHOM/ET/67/L82 were grown in axenic culture at 
37 °C in SM medium52 at pH 5.4 supplemented with 10 % heat-inactivated fetal bovine 
serum under an atmosphere of 5 % CO2 in air. 100 µL of culture medium with 105 
amastigotes from axenic culture with or without a serial drug dilution were seeded in 96-
well microtiter plates. Serial drug dilutions of eleven 3-fold dilution steps covering a 
range from 90 to 0.002 μg/mL were prepared. After 70 h of incubation the plates were 
inspected under an inverted microscope to assure growth of the controls and sterile 
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conditions. 10 μl of Alamar Blue (12.5 mg resazurin dissolved in 100 mL distilled water)53 
were then added to each well and the plates incubated for another 2 h. Then the plates 
were read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices 
Cooperation, Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an 
emission wave length of 588 nm. Data were analyzed using the software Softmax Pro 
(Molecular Devices Cooperation, Sunnyvale, CA, USA). Decrease of fluorescence 
(= inhibition) was expressed as percentage of the fluorescence of control cultures and 
plotted against the drug concentrations. From the sigmoidal inhibition curves the IC50 
values were calculated. 
3.5.10 Activity against L. donovani intracellular amastigotes: macrophage assay54 
Mouse peritoneal macrophages (4 x 104 in 100 µl RPMI 1640 medium with 10% heat-
inactivated FBS) were seeded into wells of Lab-tek 16-chamber slides. After 24 hrs 1.2 x 
105 amastigote Leishmania donovani in 100 µl were added. The amastigotes were taken 
from an axenic amastigote culture grown at pH 5.4. Four hrs later the medium containing 
free amastigote forms was removed and replaced by fresh medium. Next day the medium 
was replaced by medium containing different compound dilutions. Parasite growth in the 
presence of the drug was compared to control wells. After 96 hours of incubation the 
medium was removed and the slides fixed with methanol for 10 min followed by a 
staining with a 10% Giemsa solution. Infected and non-infected macrophages were 
counted for the control cultures and the ones exposed to the serial drug dilutions. The 
infection rates were determined. The results were expressed as % reduction in parasite 
burden compared to control wells, and the IC50 calculated by linear regression analysis. 
3.5.11 Activity against P. falciparum 
In vitro activity against erythrocytic stages of P. falciparum was determined using a 3H-
hypoxanthine incorporation assay55,56, using the drug sensitive NF54 strain57 and the 
standard drug chloroquine (Sigma C6628). Compounds were dissolved in DMSO at 
10 mg/mL and added to parasite cultures incubated in RPMI 1640 medium without 
hypoxanthine, supplemented with HEPES (5.94 g/L), NaHCO3 (2.1 g/L), neomycin 
(100 U/mL), AlbumaxR (5 g/L) and washed human red cells A+ at 2.5 % haematocrit 
(0.3 % parasitaemia). Serial drug dilutions of eleven 3-fold dilution steps covering a range 
from 100 to 0.002 μg/ml were prepared. The 96-well plates were incubated in a 
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humidified atmosphere at 37 °C; 4 % CO2, 3 % O2, 93 % N2. After 48 h 50 μl of 3H-
hypoxanthine (= 0.5 μCi) was added to each well of the plate. The plates were incubated 
for a further 24 h under the same conditions. The plates were then harvested with a 
Betaplate™ cell harvester (Wallac, Zurich, Switzerland), and the red blood cells 
transferred onto a glass fibre filter then washed with distilled water. The dried filters 
were inserted into a plastic foil with 10 ml of scintillation fluid, and counted in a 
Betaplate™ liquid scintillation counter (Wallac, Zurich, Switzerland). IC50 values were 
calculated from sigmoidal inhibition curves by linear regression51 using Microsoft Excel. 
Chloroquine and artemisinin are used as control. 
3.5.12 In vitro cytotoxicity with L-6 cells 
Assays were performed in 96-well microtiter plates, each well containing 100 l of RPMI 
1640 medium supplemented with 1 % l-glutamine (200 mM) and 10 % fetal bovine serum, 
and 4000 L-6 cells (a primary cell line derived from rat skeletal myoblasts).58,59 Serial drug 
dilutions of eleven 3-fold dilution steps covering a range from 100 to 0.002 μg/ml were 
prepared. After 70 h of incubation the plates were inspected under an inverted 
microscope to assure growth of the controls and sterile conditions. 10 l of Alamar Blue 
was then added to each well and the plates incubated for another 2 h. Then the plates 
were read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices 
Cooperation, Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an 
emission wave length of 588 nm. The IC50 values were calculated by linear regression51 
from the sigmoidal dose inhibition curves using SoftmaxPro software (Molecular Devices 
Cooperation, Sunnyvale, CA, USA). Podophyllotoxin (Sigma P4405) is used as control. 
3.5.13  Inhibition assay with 20S proteasome from yeast 
Compounds were assayed for inhibition of the 20S proteasome as previously described,60 
but using 0.5 nM of 20S proteasome from Saccharomyces cerevisiae (Enzo Life Sciences). 
3.5.14 Crystallization and structure elucidation 
yCP crystals were grown in hanging drop plates at 20 °C as previously described,8,61 using 
a protein concentration of 40 mg/mL in Tris/HCl (20 mm, pH 7.5) and EDTA (1 mm). 
The drops contained 1 μL of the reservoir solution consisting of 30 mm MgAc2, 100 mm 
morpholino-ethane-sulfonic acid (MES) (pH 7.2) and 10% (v/v) 2-methyl-2,4-pentanediol 
as well as 1 μL of protein. Crystals appeared after 48 h and were then soaked with 
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macyranone A in DMSO at final concentrations of 10 mm for 12 h following 
complementation of the droplets with cryoprotecting buffer consisting of 30% (w/v) 2-
methyl-2,4-pentanediol, 20 mm MgAc2, 100 mm MES (pH 6.9). The crystals were 
supercooled in a stream of liquid nitrogen gas at 100 K (Oxford Cryo Systems). The 
dataset of yCP:macyranone A structure was collected with 2.8 Å resolution using 
synchrotron radiation (λ = 1.0 Å) at the X06SA-beamline (Swiss Light Source, Villingen, 
Switzerland, Table S8). X-ray intensities were assessed with the program XDS62 and data 
reduction was carried out using XSCALE62. The molecular replacement started with the 
coordinates of yCP (pdb entry code: 1RYP) and Translation/Libration/Screw (TLS) 
refinements were performed with REFMAC5 in the CCP4i suite.63 Model building was 
carried out using the program package MAIN.64 
3.5.15 Proteasome purification 
20S proteasome from Saccharomyces cerevisiae (yCP) was purified as previously described.8 
The yeast cells were lysed in a continuous cell disruption system and centrifuged at 
40,000 g. The suspension was applied to a phenyl sepharose HIC column after 
precipitation in aqueous 40% (NH4)2SO4. Eluted fractions with 20S proteasome activity 
were pooled and purified using a FPLC system with hydroxyapatite column. The 
polishing was performed via a Resource-Q anion exchange column and Superose 6 size 
exclusion chromatography. Pooled fractions were concentrated to 40 mg/mL in 20 mm 
Tris (pH 7.5) and used for vitro assays and crystallization trials.  
3.5.16 IC50 value determination 
The in vitro proteasome inhibition assays were performed with fluorescence assays in 96-
well plates. The assay mixtures contained 10 μg/mL of commercially available purified 
human cCP (Boston Biochem) and human iCP (Boston Biochem) in 100 mm Tris/HCl (pH 
7.5) buffer. Inhibitors were dissolved in DMSO and added at various concentrations with 
three repetitions each, with a final concentration of less than 10% (w/v) DMSO. After the 
incubation time of 60 min at RT, the fluorogenic substrate Suc-Leu-Leu-Val-Tyr-AMC 
(Bachem) was added to measure the residual activity of the chymotrypsin-like site. 
Afterwards, the assay mixture was incubated for another hour at RT and fluorescence 
was determined on a Varian Cary Eclipse photofluorometer with excitation and emission 
wavelengths of λexc = 360 and λem = 460 nm, respectively. 
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3.6 Supporting Information 
3.6.1 Structure elucidation 
Table S1. NMR spectroscopic data for macyranone A (1) (methanol-d4) 
 
 
δCa δHb mult (J, Hz) HMBCc COSYd 
Phe 1 174.7 
    
 2 55.1 4.68 dd (9.0, 4.8) 1, 3, 4, 1MMA 3a, 3b 
 3a 38.3 3.26 dd (14.1, 4.8) 1, 2, 4, 5 2, 3b 
 3b 
 
2.98 o 1, 2, 4, 5 2, 3a 
 4 138.3 
    
 5 130.2 7.23 d (7.5) 3, 7 6 
 6 129.4 7.28 t (7.5) 4, 6 5, 7 
 7 127.8 7.21 t (7.5) 5 6 
Mma 1 173.2 
    
 2 48.2 3.33 d (7.2) 1, 3, 4 4 
 3 173.2 
    
 4 15.9 1.26 d (7.2) 1, 2, 3 2 
Thr 1 172.3 
    
 2 60.2 4.34 d (4.0) 1, 3, 4, 3MMA 3 
 3 68.2 4.17 dq (6.4, 4.0) 1, 2, 4 2, 4 
 4 19.7 1.16 d (6.4) 2, 3 3 
aThr 1 172.4 
    
 2 59.8 4.37 d (6.2) 1, 3, 4, 1Thr 3 
 3 68.6 4.04 dq (6.3) 1, 2, 4 2, 4 
 4 19.6 1.20 d (6.3) 2, 3 3 
Leu 1 207.6 
    
 2 54.1 4.50 dd (10.4, 4.0) 1, 3a, 3b, 4, 1aThr 3a, 3b 
 3a 39.7 1.55 m 1, 2, 4, 5, 6 2, 3b, 4 
 3b 
 
1.50 m 1, 2, 4, 5, 6 2, 3a, 4 
 4 25.9 1.72 m 2, 3, 5, 6 3, 5, 6 
 5 21.5 0.92 d (6.5) 3, 4, 6 4 
 6 23.5 0.96 d (6.7) 3, 4, 5 4 
 1' 52.8 3.63 dd (4.8, 2.4) 1, 2, 2'a, 2'b 2'a, 2'b 
 2'a 47.5 3.02 dd (4.9, 6.1) 1, 1' 1', 2'b 
 2'b 
 
2.98 dd (2.4, 6.1) 1, 1' 1', 2'a 
aRecorded at 175 MHz; referenced to residual methanol-d4 at δ 49.15 ppm. 
bRecorded at 700 MHz; referenced to residual methanol-d4 at δ 3.31 ppm. 
cProton showing correlation to indicated carbon. 
dProton showing correlation to indicated proton. 
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Table S2. NMR spectroscopic data for macyranone B-F (2-6) (methanol-d4) 
 Macyranone B Macyranone C Macyranone D Macyranone E Macyranone F 
 δCa δHb δCa δHb δCa δHb δCa δHb δCa δHb 
Phe           
1 174.8 
 
-- 
 
177.9 
 
174.6 
 
175.4  
2 55.8 4.69 55.5 4.70 57.2 4.59 55.0 4.70 55.5 4.67 
3a 38.5 3.26 39.0 3.26 38.8 3.32 38.2 3.25 38.3 3.27 
3b 
 
2.96 
 
2.98 
 
2.93 
 
2.98 
 
2.96 
4 138.3 
 
-- 
 
139.4 
 
138.2 
 
138.5 
 
5 130.2 7.23 131.3 7.23 130.3 7.26 130.2 7.23 130.3 7.23 
6 129.2 7.27 130.2 7.28 129.3 7.26 129.4 7.27 129.3 7.27 
7 127.5 7.21 128.5 7.21 127.5 7.19 127.7 7.21 127.7 7.20 
Mma           
1 173.0 
 
-- 
 
173.2 
 
173.2 
 
173.3  
2 47.9 3.33 49.0 3.34 48.7 3.35 48.2 3.33 48.3 3.32 
3 173.1 
 
-- 
 
173.4 
 
173.2 
 
173.4 
 
4 15.7 1.24 16.8 1.26 15.5 1.25 16.0 1.26 15.8 1.24 
Thr           
1 172.3 
   
172.6 
 
172.3 
 
172.6 
 
2 60.4 4.33 61.2 4.33 60.3 4.32 60.1 4.34 60.2 4.34 
3 68.0 4.17 68.9 4.17 68.3 4.20 68.2 4.15 68.2 4.17 
4 19.6 1.16 20.5 1.16 19.9 1.12 19.7 1.12 19.6 1.15 
aThr           
1 171.9 
 
-- 
 
172.4 
 
172.0 
 
172.2 
 
2 58.8 4.37 60.9 4.37 61.0 4.20 59.9 4.36 56.7 4.43 
3 68.4 4.00 69.3 4.06 68.3 4.02 68.5 4.00 62.6 3.76 
4 19.2 1.17 20.5 1.22 20.3 1.18 19.5 1.09 
  
 Abf 
 
Leu 
 
His 
 
Trp 
 
His 
 
1 212.0 
 
-- 
 
209.8 
 
212.1 
 
212.2 
 
2 87.4 
 
59.3 4.40 58.5 4.68 60.1 4.72 60.3 4.70 
3a 45.0 1.66 40.9 1.52 26.5 3.25 27.7 3.22 27.6 3.22 
3b 
 
1.62   
 
2.95 
 
3.10 
 
3.12 
4 24.8 1.67 26.6 1.67 131.6 
 
110.6 
 
110.6 
 
5 24.3 0.97 24.4 0.94 118.6 7.19 128.4 
 
128.5 
 
6 24.1 0.88 22.3 0.89 134.8 8.43 119.1 7.53 119.1 7.53 
7       119.8 7.01 119.7 7.01 
8       122.4 7.08 122.3 7.08 
9   
  
  112.2 7.32 112.3 7.32 
10   
    
137.9 
 
138.0 
 
11 
      
124.4 7.07 124.4 7.08 
1`a 65.9 4.34 33.7 2.56 33.3 2.67 34.4 2.46 34.3 2.45 
1`b 
 
4.18   
 
2.52 
 
2.35 
 
2.35 
2`a 37.5 2.78 8.4 0.99 7.7 1.01 7.4 0.89 7.4 0.86 
2`b  2.50         
aRecorded at 175 MHz; referenced to residual methanol-d4 at δ 49.15 ppm. 
bRecorded at 700 MHz; referenced to residual methanol-d4 at δ 3.31 ppm. 
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Figure S1. Key HMBC (red arrows) and COSY (thick bonds) correlations for macyranone A (1)  
 
Table S3. Retention times of the D- and L-FDLA derivatized amino acid residues received from 
hydrolysis of the macyranones compared to the respective standards 
amino 
acid 
detected 
m/z 
Macyranone A Macyranone B Macyranone C Standard 
D-FDLA L-FDLA D-FDLA L-FDLA D-FDLA L-FDLA D-FDLA L-FDLA 
L-Phe 460.18 22.16 18.95 22.13 18.93 22.18 18.94 21.49 18.26 
L-Thr 414.16 16.08 13.03 16.05 13.00 16.10 13.03 15.36 12.38 
L-allo-
Thr 
414.16 14.81 13.59 14.79 13.55 14.83 13.59 14.09 12.91 
L-Ser 400.15 -- -- -- -- -- -- 13.07 12.55 
L-Leu 426.20 
22.69/ 
22.85 
18.53/ 
18.79 
22.67/ 
22.84 
18.49/ 
18.75 
22.72/ 
22.89 
18.54/ 
18.78 
22.05/ 
22.19 
17.84/ 
18.10 
L-His 450.17 -- -- -- -- -- -- 9.35 10.42 
amino 
acid 
detected 
m/z 
Macyranone D Macyranone F Macyranone F   
D-FDLA L-FDLA D-FDLA L-FDLA D-FDLA L-FDLA   
L-Phe 460.18 21.52 18.25 22.18 18.93 21.52 18.27   
L-Thr 414.16 15.38 12.37 16.09 13.04 15.38 12.39   
L-allo-
Thr 
414.16 14.15 12.91 14.83 13.58 -- --   
L-Ser 400.15 -- -- -- -- 13.09 12.55   
L-Leu 426.20 -- -- -- -- -- --   
L-His 450.17 9.29 10.30 -- -- -- --   
           Macyranones 115 
 
 
 
Figure S2. J based configuration analysis of macyranone E to confirm the L-allo-configuration of 
aThr.24 The large coupling constant between H2-aThr and H3-aThr gives rise to the two possible 
rotamers 1 and 2 with anti-orientation of the respective protons and allows their discrimination 
and the assignment of the erythro configuration based on a key ROE correlation between the 
methyl protons Me4-aThr and the amine proton NH-aThr. 
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3.6.2 Feeding experiments using labeled precursors 
 
Figure S3. Isotopic peak pattern of the highly abundant [M+H]+ signals for macyranone A (607 
m/z) prove incorporation of labeled L-leucine as well as sodium propionate and acetate in 
MCy9118. The observed mass shifts fit to the heavy isotopes that were incorporated.  
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3.6.3 Biosynthetic gene cluster analysis 
The biosynthetic gene cluster was identified using the antiSMASH 2.0 software tool.26 The 
biosynthetic gene cluster spans 21,003 bp and consists of 8 open reading frames (ORFs) 
named mynA to mynH. It has an overall GC content of 70.0%. The catalytic domains were 
annotated using antiSMASH 2.0, Pfam46, NRPS predictor247, and PKS/NRPS Analysis48. 
Genes that did not allow a prediction for PKS or NRPS domains were analyzed via the 
BLAST algorithm.27 
 
Table S4. Deduced functions of ORFs in the macyranone biosynthetic gene cluster 
Gene AA Protein homolog 
Simila
rity 
reference Proposed function 
mynA 603 PdmN, Actinomadura hibisca 42 % ADB23384 amidotransferase 
mynB 509    stand-alone AThr domain 
mynC 588 
Butyryl-CoA dehydrogenase, 
Streptomyces sp. NRRL S-1022 
67 % WP_030347517 acyl-CoA dehydrogenase 
mynD 3058    
NRPS (C-PCP, C-AThr-PCP, C-
ALeu-PCP) 
mynE 411 
MFS transporter permease, 
Saccharothrix sp. NRRL B-
16314 
38 % WP_033439102 transporter 
mynF 527 
Peptide synthetase, 
Streptomyces griseus 
51 % WP_003964446 stand-alone AHis domain 
mynG 997    PKS (KS-AT-ACP) 
mynH 258 
thioesterase, Amycolatopsis 
mediterranei 
44 % WP_013230025 thioesterase type II 
A: adenylation domain, ACP: acyl-carrier-protein domain AT: acyltransferase domain, C: condensation 
domain, KS: ketosynthase domain, PCP: peptidyl-carrier-protein domain 
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3.6.3.1 MynA analysis 
 
Figure S4. Amino acid sequence alignment of MynA with selected homologs. Yellow is the N-
terminal glutaminase and blue the C-terminal amide synthetase domain. Arrows indicate active 
side residues that are consistent (green) or not (red) between MynA and AS B. Accession numbers 
for each of the enzymes are: RubR: AAM97368; PdmN: ABK58686; FdmV: AAQ08933; AS B: 
NP_415200. 
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3.6.3.2 A domain analysis 
Three NRPS modules were identified in the biosynthetic gene cluster but in total four 
adenylation domains. Two of the adenylation domains represent discrete proteins. The A 
domain specificity was determined using the online tool NRPSpredictor247 based on the 
extracted Stachelhaus code.62 The results are listed in Table S5. The predicted specificities 
of A domains 1-3 is consistent with the observed amino acids incorporated into the main 
product macyranone A. The fourth adenylation domain shows substrate specificity for 
histidine. Since histidine is incorporated in macyranone D, the domain might act as 
alternative adenylation domain for module three. Still, no adenylation domain with 
tryptophan specificity could be identified to explain the occurrence of macyranone E and 
F.  
 
Table S5. Analysis of the adenylation domain substrate specificity based on the Stachelhaus code 
using NRPSpredictor247 
Adenylation 
domain 
The extracted Stachelhaus code using NRPSpredictor 2 
Predicted amino 
acid[a] 
MynB-A1 D F F N I G T V F K Thr [b] 
MynD-A2 D F W N I G M V H K Thr [c] 
MynD-A3 D A W F M I A V V K Leu [b] 
MynF-A4 D S A L I A E V W K His [b] 
[a] substrate specificities as predicted by comparison of the 10 amino acid code deefindet by Stachelhaus et al.62 
[b] predictions with lower confidence (70%) 
[c] predictions with high confidence (100%) 
 
3.6.3.3 C domain analysis 
The C domains myn biosynthetic gene cluster were analyzed using NaPDoS.49 MynD-C2 
and –C3 are characterized as LCL-type condensation domains. This result confirms that 
both domains catalyze the formation of a peptide bond between two l-amino acids.  
MynD-C1 does not group with any of the known C domain types. The result emphasizes 
the hypothesis, that the first condensation domain is involved in the biosynthesis of the 
unusual starter unit. It is a likely candidate for the catalysis of amide bond formation 
between the methylmalonate-phenylalanine biolding block and the first threonine that is 
selected and activated by the first adenylation domain identified in the gene cluster.  
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Figure S5. Phylogenetic tree highlighting different C domain types and the C-domains 
found in the myn biosynthetic gene cluster in Cystobacter fuscus MCy9118.  
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3.6.3.4 KS domain analysis 
The ketosynthase (KS) domain of the myn was extracted and analyzed using NaPDoS.49 
The resulting phylogenetic tree shown in Figure S6 allows the assignment of the KS 
domain as PKS/NRPS hybrid KS domain. This assignment confirms the gene cluster 
analysis that the KS domain is situated downstream of a PCP domain (PCP3 on MynD) 
and catalyzes the condensation reaction between an amino acid and an acyl precursor.  
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Figure S6. Phylogenetic tree highlighting different KS domain types and the KS domain found in 
the myn biosynthetic gene cluster in Cystobacter fuscus MCy9118 confirming it as hybrid KS 
domain 
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3.6.3.5 AT domain analysis 
The substrate specificity of the acyl transferase (AT) domain encoded by mynG was 
analyzed using conserved motif analysis and comparison to the AT domains from the 
known epoxyketone biosynthetic gene clusters from epoxomicin and eponemycin. The 
domains were aligned to a reference AT from E.coli FAS, 1MLA (PDB 1MLA, UniProtKB 
P0AAI9) (Table S6). The data show that the three AT contain the GxSxG consensus motif 
with the catalytic serine residue. Even if the three AT domains are suspected to 
incorporate the same building block (most likely malonyl-CoA), the active site analysis to 
predict the used extender unit based on the amino acid position 200 in 1MLA is 
inconsistent. Ser200 as in EpnH supports mm-CoA and Phe200 as in EpxE supports m-
CoA whereas various different residues like Gln200 could not be unequivocally assigned 
to a substrate. The incorporation of an unusual residue and conversion to the 
epoxyketone residue can therefore not be excluded. 
 
 
Table S6. Active site analysis of the acyl transferase domains (AT) according to Yadav et al.63 from 
the three PKS ancoded by the myn, the epn and epx biosynthetic gene clusters from eponemycin 
and epoxomicin, respectively  
AT domain observed predicted 11 63 90 91 92 93 94 117 200 201 231 250 255 
MynG-AT m-CoA ? Q Q G H S L G R G H D H I 
EpnH-AT m-CoA mm-CoA H Q G N S V G R S H T H V 
EpxE-AT m-CoA m-CoA Q Q G N S I G R F H N H V 
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3.6.3.6 TE domain analysis 
 
Figure S7. Phylogenetic tree analysis of various type I and II TE proteins from PKS and NRPS 
systems. The characterization as type I or type II thioesterase reflect whether the TE exists as an 
integral domain within a PKS or NRPS subunit (type I) or as discrete proteins (type II). The type of 
cluster to which each TE belongs is given (P, PKS; N, NRPS; PN, PKS/NRPS hybrid; *function 
assigned on the basis of genome annotation). Branch length indicates the number of inferred 
amino acid changes per position.  
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3.6.4 Targeted inactivation of the myn locus in MCy9118 
 
Figure S8. Left side: Principle of homologous recombination and PCR verification used for the 
Cystobacter fuscus MCy9118 knockout mutants; Right: Verification of mutants MCy9118::mynAKO, 
MCy9118::mynCKO and MCy9118::mynDKO using PCR 
Table S7. Primers used for amplification and verification of the macyranone single crossover 
knock-out mutants in Mcy9118 
MynD KO  
mynDKOFor TGATTGATTGAGGTGGTCGACCGGGCCTCCCTG 
mynDKORev TCAATCAATCACGGCAGCAGCAAGGCCACCAGTTC 
Verify_mynDKO_for GAGGTTGGCTGGCACTGGTTG 
Verify_mynDKO_rev CAGCATCGCCTGGACCTGCTC 
MynA KO  
mynAKOFor TGATTGATTGATCCAGCGCGCTGACGGGCCTG 
mynAKORev TCAATCAATCATACGCGCAATCGACGGAGCCAGC 
Verify_mynAKO_for CGGTCCTGCTCTCTGGTGGTC 
Verify_mynAKO_rev GTGAAGAGACTAGAGCTTGACGCG 
MynC KO  
mynCKOFor TGATTGATTGAGACCGCCAGCTCCCTGACGG 
mynCKORev TCAATCAATCACAGGAACCGCTCGACCGGGAC 
Verify_mynCKO_for CTGCTTCGCGAGCGAATCGAC 
Verify_mynCKO_rev GTAGTACGACAGGATCGACATCCG 
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3.6.5 X-ray analysis of macyranone A in complex with yeast 20S proteasome 
Table S8. Crystallographic data collection and refinement statistics of yCP in complex with 
macyranone A. 
 
 
*Dataset has been collected on a single crystal. 
†Values in parentheses of resolution range, completeness, Rmerge, and I/σ (I) correspond to the last resolution 
shell. 
‡Friedel pairs were treated as identical reflections. 
§Rmerge (I) = ΣhklΣj |[I(hkl)j-I(hkl)]|/ Σhkl Ihkl, where I(hkl)j is the measurement of the intensity of reflection hkl 
and <I(hkl)> is the average intensity. 
¶R = Σhkl||Fobs| − |Fcalc||/Σhkl|Fobs|, where Rfree is calculated without a sigma cut off for a randomly chosen 
5% of reflections, which were not used for structure refinement, and Rwork is calculated for the remaining 
reflections. 
**Deviations from ideal bond lengths/angles. 
***Number of residues in favored region/allowed region/outlier region. 
 
  
Crystallographic data yCP:macyranone A* 
 
Crystal parameters 
Space group 
Cell constants 
(dataset was collected from 
1 crystal / 1 CP per AU) 
 
P21 
a = 133.67 Å 
b = 300.70 Å 
c = 143.99 Å 
β = 112.52 ° 
 
Data collection 
Beamline 
Wavelength, (Å) 
Resolution range, (Å)† 
No. observations 
No. unique reflections‡ 
Completeness, (%)† 
Rmerge, (%)†,§ 
I/σ (I)† 
 
 
X06SA, SLS 
1.0 
30-2.8 (2.9-2.8) 
773,359 
250,454 
97.4 (97.0) 
6.0 (49.0) 
14.6 (2.7) 
 
Refinement (REFMAC5)  
Resolution range, (Å) 
No. reflections working set 
No. reflections test set 
No. non-hydrogen 
No. ligand atoms 
Water, Mg2+ 
Rwork/Rfree (%)¶ 
RMSD bond (Å)/(°)** 
Average B-factor (Å2) 
Ramachandran plot, %*** 
 
 
15-2.8 
237,931 
12,523 
49,929 
300 
368 
19.4/21.9 
0.005/0.96 
72.8 
97.5/2.3/0.2 
 
PDB accession code 
 
5AHJ 
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3.6.6 NMR spectra 
 
1H NMR spectrum of macyranone A (1) in CD3OD, 700 MHz 
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13C NMR spectrum of macyranone A (1) in CD3OD, 125 MHz 
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HSQC spectrum of macyranone A (1) in CD3OD, 700 MHz  
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HMBC spectrum of macyranone A (1) in CD3OD, 700 MHz 
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COSY spectrum of macyranone A (1) in CD3OD, 700 MHz 
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1H NMR spectrum of macyranone B (2) in CD3OD, 700 MHz 
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HSQC spectrum of macyranone B (2) in CD3OD, 700 MHz  
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HMBC spectrum of macyranone B (2) in CD3OD, 700 MHz 
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COSY spectrum of macyranone B (2) in CD3OD, 700 MHz  
 
           Macyranones 137 
 
 
1H NMR spectrum of macyranone C (3) in CD3OD, 700 MHz 
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HSQC spectrum of macyranone C (3) in CD3OD, 700 MHz  
           Macyranones 139 
 
 
COSY spectrum of macyranone C (3) in CD3OD, 700 MHz  
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1H NMR spectrum of macyranone D (4) in CD3OD, 700 MHz 
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HSQC spectrum of macyranone D (4) in CD3OD, 700 MHz  
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HMBC spectrum of macyranone D (4) in CD3OD, 700 MHz 
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COSY spectrum of macyranone D (4) in CD3OD, 700 MHz  
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1H NMR spectrum of macyranone E (5) in CD3OD, 700 MHz 
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13C NMR spectrum of macyranone E (5) in CD3OD, 125 MHz 
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HSQC spectrum of macyranone E (5) in CD3OD, 700 MHz  
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HMBC spectrum of macyranone E (5) in CD3OD, 700 MHz 
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COSY spectrum of macyranone E (5) in CD3OD, 700 MHz  
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1H NMR spectrum of macyranone F (6) in CD3OD, 700 MHz 
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HSQC spectrum of macyranone F (6) in CD3OD, 700 MHz  
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HMBC spectrum of macyranone F (6) in CD3OD, 700 MHz 
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COSY spectrum of macyranone F (6) in CD3OD, 700 MHz 
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4 Discussion 
The main achievement of this thesis was the identification and full characterization of two 
novel natural product classes from the myxobacterium Cystobacter fuscus MCy9118 as well 
as their association with the corresponding biosynthetic pathways. It includes several 
aspects of the field of natural products (NP) research. The myxobacterial strain was 
deeply analyzed with regard to the produced compounds to profile the biosynthetic 
potential of the strain. As a consequence, the thesis deals with the isolation of natural 
products using a chemical screening approach based on LC-MS-SPE-NMR as well as the 
full de novo structural characterization of the identified natural products. This goes along 
with the identification and characterization of the biosynthetic machinery that underlies 
the production of the diverse compounds and studies concerning their biological activity. 
4.1 The NP Isolation Approach – a Question of Faith? 
The effectivity of a chemical screening approach for new molecular structures using 
hyphenated chromatographic techniques was clearly proven in this work but as 
illustrated in the introduction, several basic approaches are applied in the search for new 
natural products. So what are the advantages and disadvantages of a biological screening 
approach, a chemical screening approach or a genome mining approach and what are the 
explicit reasons to apply the one or the other? 
The search for new natural products can nicely be compared to the well-known concept 
of a needle in a haystack without even knowing how the needle looks like. In microbial 
crude extracts, the diverse target molecules represent only a tiny fraction. Many 
approaches have been applied to isolate new natural products but not every approach can 
be equally promising in all cases and it is a matter of fact that the applied approach is the 
decisive factor that differentiates between success and failure. The central question is 
which approach is the one to apply in a specific case? Therefore, some fundamental 
considerations have to be taken into account which evaluate the factual circumstances 
and therefore allow a decision: 
1) The objective needs to be clearly defined whether for example the isolation of a 
compound that shows a specific bioactivity, that acts on a specific target or that 
exhibits a new chemical scaffolds is the aim. 
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2) Considerations about the local circumstances are necessary like the available 
techniques since for example a chemical approach depends more on high-quality 
analytical techniques whereas for a biological screening one needs a constant 
access to biological testing. 
3) The knowledge about the producing organism is crucial. Is the organism 
culturable and does it produce secondary metabolites under laboratory 
conditions? Are already secondary metabolites known from the organism? Are 
genome sequence data available or accessible which would be a requirement for a 
genome-based approach?  
If the objective, in our case the isolation of natural products that exhibit new chemical 
scaffolds, is defined and the local circumstances are considered, the third point indicates 
that the NP isolation approach is still a case-to-case decision for every organism. It 
strongly depends on the prerequisites that every organism, that is a candidate for the 
screening process, provides. 
4.1.1 The NP isolation approach in case of Cystobacter fuscus MCy9118 
The decision-making process concerning the NP isolation strategy is preceded by initial 
testing of the organisms for culturability and bioactivity as well as MS based dereplication 
to identify already known compounds.  
C. fuscus was found to exhibit a wide range of biological activities against Gram-positive 
and Gram-negative bacteria as well as fungi. Together with a good culturability allowing 
the production of sufficient material, this would enable a traditional bioactivity-guided 
isolation approach. However, the dereplication process using the “Myxobase” based on 
retention time in a defined analytical system, high-resolution m/z value and isotope 
pattern fit1 showed the presence of already known secondary metabolites. This method 
identified the typical myxobacterial catechole siderophores myxochelin A2 and B3, that 
show weak activity against some Gram-positive bacteria.  
Additionally, the strain produced the unstable roimatacene, a compound with moderate 
activity only against Gram-negative bacteria.4 Due to the instability of the compound, the 
MS based dereplication method failed in the first line and only manual inspection of the 
produced LC-MS data in combination with NMR data from LC-NMR resulted in a correct 
assignment of the compound. The last known antibiotic produced by the strain was 
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althiomycin exhibiting a broad and potent antimicrobial activity against several Gram-
positive and Gram-negative bacteria (Figure 4.2-C).5,6 
Even if the production of these diverse compounds with such biological activities is 
exciting with respect to the enormous biosynthetic potential of this specific strain, 
particularly the wide range of bioactivities of the known compounds made an assignment 
of the bioactivity to a specific compound impossible. Therefore, the application of a 
bioactivity-guided isolation approach was unfavorable. Additionally, the genome 
sequence of the strain had not been known from the outset, so that the decision was made 
in favor of a chemical screening approach based on LC-SPE-NMR-MS (Figure 4.1). 
 
Figure 4.1 Decision tree of natural product isolation approaches with regard to the strategy used 
for Cystobacter fuscus MCy9118. Green: biological screening; blue: chemical screening; red: genome 
mining: y, yes; n, no. 
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Figure 4.2: Representation of the full chemical potential of Cystobacter fuscus MCy9118. A: Chemical 
structures of the macyranones. B: Chemical structures of the cystomanamides. C: Chemical 
structures of known secondary metabolites produced by the strain. 
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In the scope of MS based dereplication, various peaks belonging to unknown compounds 
were identified. In this approach, the hyphenated LC-NMR technique was used to 
identify interesting target compounds out of these unknown compounds produced by the 
strain. Because of the work with small-scale cultivation as well as the intrinsic low 
sensitivity of NMR spectroscopy even with a cryogenic flow probe, the amount of 
compounds present in the crude extract was critical for the analysis by LC-NMR. The 
crude extract was analyzed and as mentioned above, the first success was the rapid 
dereplication of the known antibiotic roimatacene. Besides that, several peaks were 
analyzed and two compounds were chosen for further analysis based on their interesting 
NMR profile exhibiting signals for peptidic as well as aliphatic residues. These two 
compounds were later named macyranone B and cystomanamide A. Using the NMR data 
obtained from LC-SPE-NMR, it was possible to identify isolated fragments of the 
compounds and get an impression of their overall nature. Nevertheless, it was necessary 
to scale-up the cultivation conditions to receive a sufficient amount of extract for further 
processing. The crude extract underwent a fractionation procedure composed of size-
exclusion chromatography and successive rounds of reversed-phase liquid 
chromatography to isolate the target compounds determined in the LC-NMR run. 
Structure elucidation of both compounds showed that both describe new molecular 
structures with unusual chemical features proving that the chemical screening approach 
was undoubtedly the right choice in case of C. fuscus MCy9118. 
4.2 From Bacteria to Compounds 
The main issue in the characterization of new natural products from myxobacteria is often 
the low yield and therefore limited amount of available compound.7–9 Even if our NMR 
system with a 700 MHz magnet and a proton optimized ‘inverse’ cryoprobe is an 
excellent basis for the measurements of minimum quantities, the extremely low amounts 
still complicate the compound characterization. In addition to the high-tech 
instrumentation, we use high-quality magnetic susceptibility matched 5mm NMR tubes, 
so called Shigemi tubes, to minimize the required amount of solvent and maximize the 
concentration of the compound for the measurements.10 Nevertheless, optimization of 
cultivation conditions and repeated isolation procedures are most of the time unavoidable 
to accumulate sufficient compound quantities. 
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4.2.1 Finding the best cultivation conditions 
In case of the major compounds of the two new compound classes, named macyranone B 
and cystomanamide A, the yield was sufficient from the beginning to isolate enough 
material from a 6 L cultivation to analyze the compounds and elucidate the planar 
structures as described in detail in Chapter 2 and 3. With less than 0.1 mg/L, the yield 
was still inadequate for further studies and required an optimization of the production 
conditions to allow the full characterization of the compounds in terms of configuration 
as well as biological activity. Inspection of the MS2 fragmentation data of the crude extract 
also indicated the presence of related compounds of both core structures being present in 
trace amounts. This kind of compound classes covering various chemical variants of one 
basic scaffold is commonly found in myxobacteria.11 Examples of such diverse compound 
classes from myxobacteria are the chondramides,12,13 the tubulysins14,15, the recently 
published cystobactamids16 as well as the microsclerodermins.17 To increase the 
production of the compounds and to enable their isolation, varying cultivation conditions 
were tested using different media, cultivation times, shake flask cultivation in baffled and 
normal flasks as well as fermentation. The best cultivation conditions were different for 
the two compound classes, but a yeast-based production medium18 turned out to be the 
best choice in both cases. Even if the best growth of the strain was observed in M-medium 
containing phytone and maltose as main components, the presence of other cells 
(autoclaved yeast cells) as well as the limited amount of nutrition in the yeast-based 
VY/2S medium could act as a stress factor for the myxobacterium and therefore induce 
the production of secondary metabolites.19 An increase of the iron concentration in the 
production medium to 8 mg/L Fe-EDTA resulted in a significant decrease of the 
produced amount of the siderophores myxochelin A and B, circumventing the tedious 
separation of these compounds.  
The macyranones reached their optimum production in shake flask cultivation with 0.4 % 
dry yeast instead of 0.5 % baker’s yeast (VY/2S-DY medium) at a shaking rate of 160 rpm. 
A shorter cultivation time of 6 to 8 days was sufficient for production of the compounds. 
Surprisingly, using the shorter cultivation time macyranone B was replaced by 
macyranone A as most abundant derivative. Using a fermenter instead of shake flask 
cultivation, the macyranone production dropped significantly. Therefore, the shake-flask 
cultivation was applied for the production of larger amounts to avoid the tedious 
optimization of the fermentation conditions. 
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Cystomanamide A and B were produced almost equally in all cultivation conditions but 
the use of a fermenter triggered the production of the glycosylated derivatives 
cystomanamide C and D. The cystomanamides reached their highest level on day 10 of 
the fermentation. Cultivation in a 100 L fermenter using the tested conditions conducted 
by Wolfgang Kessler at the Helmholtz-Centre for Infection Research in Braunschweig 
unfortunately did not result in the desired production so that a 10 L fermentation was the 
method of choice. 
4.2.2 Isolation of the target compounds 
Coming to the isolation of natural products, Richard J. P. Cannell found the right words 
to describe the challenge: “It can seem a formidable task, faced with a liter of fermentation 
broth - a dark, viscous sludge - knowing that in there is one group of molecules that has 
to be separated from all the rest.”20 Even if the fermentation broth of C. fuscus is more of a 
bright orange to pinkish color, the task remains the same. 
The use of an adsorber resin is one step to facilitate the extraction procedure since it 
allows solid-phase extraction. The target compounds stick to the adsorber (given that it is 
the right one) and can therefore be easily separated from the fermentation broth. For both 
compound families, the addition of 2 % Amberlite XAD-7 adsorber resin was even 
advantageous for the yield. It increased the production of the secondary metabolites 
suggesting a feedback inhibition by the end products that can be prevented or reduced by 
the addition of an adsorber resin.21 A similar feedback inhibition by the end-product was 
found in the biosynthesis of the epothilone.22 All compounds but cystomanamide B were 
found attached to the XAD, only cystomanamide B was yielded by extraction of the 
centrifuged cell mass.  
4.2.3 Characteristics of the compounds 
The new natural products of the class of cystomanamides are characterized by an unusual 
3-amino-9-methyldecanoic acid (AMDA) residue, which is N-glycosylated in case of 
cystomanamide C and D, and several non-proteinogenic amino acid residues. These 
comprise -hydroxylated amino acids namely -hydroxy asparagine (-OH-Asn) and -
hydroxy phenylalanine (-OH-Phe) as well as D-amino acids like D-asparagine. D-tyrosine 
is found in cystomanamide B. Additionally, cystomanamide B bears an unusual glyceric 
acid (GA) residue (Figure 4.2-B). There are only a few peptides known where a glyceric 
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acid residue is present23–26 but among them, cystomanamide B is the only peptide, where 
the GA residue is integrated into the peptide chain and does not represent the N-terminal 
residue. Also the unprecedented 3-amino-9-methyldecanoic acid cannot be found in any 
known natural product. The residue is a branched chain fatty acid with a modification of 
the chain in the β-position. The incorporation of branched-chain fatty acids is a more 
common motif in lipopeptidic secondary metabolites as exemplified by tauramamide and 
polymyxin.27,28 The presence of an amine in the β-position of an acyl chain is unusual but 
was shown and studied in detail for mycosubtilin, a natural product that belongs to the 
iturin family.29  
The macyranones are a diverse class of peptidic compounds with an unusual 
2-methylmalonamide (Mma) residue found in all macyranones. The compounds contain 
mainly L-amino acids sharing a phenylalanine (Phe) as well as two threonine residues Thr 
and Thr’ whereas Thr’ is substituted by serine (Ser) in macyranone F. Thr’ reveals the 
unusual erythro 2S, 3S configuration. The macyranones all bear an additional variable 
amino acid residue that is substituted with an ethyl unit at the C terminus. Macyranone A 
to C contain L-leucine as C-terminal amino acid and in case of the most abundant 
derivative macyranone A, the α-amino ketone fragment is converted into an α’,β’-
epoxyketone. This compound was shown to be instable and undergoes a rearrangement 
of the epoxide ring resulting in the furanone ring found in macyranone B. Macyranone C-
F bear the unsubstituted ethyl unit with L-histidine found in macyranone D and L-
tryptophan in macyranone E and F (Figure 4.2-A).  
Several other α’,β’-epoxyketones are found in the diverse group of microbial natural 
products. Up to date, epoxyketones have mainly been isolated from actinobacteria30–33 
and with the recent discovery of the carmaphycins34 also from cyanobacteria. The 
epoxyketone natural products are discussed in detail in chapter 3. As another structural 
element, the macyranones bear the 2-methylmalonamide residue. This highly unusual 
residue is only found in the proteasome inhibitors TMC-89A and B, isolated from 
streptomyces sp. TC 1087.32 The macyranones are the first natural products where both 
functional groups of this residue are derivatized with an amino acid residue. 
In total, both compound families represent unusual natural products with unprecedented 
structural elements. 
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4.3 From Compounds to Genes 
To link a compound to its biosynthetic gene cluster, a retrobiosynthetic approach can be 
helpful to get an impression how the cluster could be assembled following textbook logic. 
Compound-specific structural elements like polyketide units or amino acid building 
blocks are considered and a hypothetic gene cluster is developed.  
The power of in silico-based analysis of genomes has largely increased over the past years. 
Several tools are available for the detailed analysis of in-silico genome data. As the most 
useful tool, antiSMASH 2.0 allows the rapid identification, annotation and analysis of 
secondary metabolite biosynthetic gene clusters.35,36 Besides the gene prediction and the 
gene cluster identification, the tool can provide details about NRPS and PKS functional 
annotation and predict a chemical structure as a possible product of the NRPS / PKS 
biosynthetic machinery.  
Figure 4.3 shows the antiSMASH 2.0 structure prediction received for the first analysis of 
the genome data from Cystobacter fuscus MCy9118 for the candidate gene clusters from the 
cystomanamides and macyranones. As described on the antiSMASH webpage, “the 
structure is a rough prediction of the core scaffold based on assumed PKS/NRPS 
colinearity where tailoring reactions are not taken into account”.37 Comparing the 
predicted structures with the actual products, it is, on the one hand, striking that the 
prediction of cystomanamide is much more detailed than the macyranone structure 
prediction. On the other hand, both predictions show a sufficient similarity to the 
products to consider the respective gene clusters as candidates for the biosynthesis of 
both compound families. Detailed analysis of both gene clusters revealed that the 
cystomanamide biosynthesis follows more the textbook rules than the macyranone 
cluster, and therefore facilitating the correct structure prediction of the cystomanamides.  
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Figure 4.3: Comparison of the chemical structures of the actual product with the predicted 
structure for the biosynthetic gene clusters for A: cystomanamide and B: macyranone from 
antiSMASH 2.0 analysis. The colors reflect the correctly predicted building blocks. 
To further analyze the catalytic domains and the A domain substrate specificity, the open 
reading frames were translated and analyzed using Pfam38, NRPS predictor239, and 
PKS/NRPS Analysis40. Genes not resulting in predictions related to PKS or NRPS 
domains were analyzed via the BLAST algorithm41 using the non-redundant sequence 
database at the National Center for Biotechnology Information (NCBI). 
4.3.1 Cystomanamide biosynthetic gene cluster 
The antiSMASH structure prediction based on the cystomanamide biosynthetic gene 
cluster was highly above average. The identified biosynthetic genes were in a good 
agreement with the predicted biochemical steps required for cystomanamide biosynthesis 
which is by far not always the case in myxobacterial biosynthetic systems.42,43 The tool 
was capable to identify all regular PKS and NRPS domains as well as the fatty acid 
loading domains (see Chapter 2). Taking into account the identified domains that were 
not implemented into the predicted structure, all amino acids as well as their 
stereochemistry were concluded correctly. The stereochemical prediction is derived from 
the fact that NRPS modules incorporate mainly naturally occurring L-amino acids 
whereas epimerization domains present in the modules are responsible for a conversion 
into the respective D-amino acid. The identification of epimerization domains in the 
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respective modules fits perfectly with the presence and position of the D-amino acids D-
asparagine, D-phenylalanine and D-tyrosine in cystomanamide B.  
Deviations between the predicted structure and the actual product result from the 
involvement of unusual biosynthetic steps as well as tailoring reactions involved in the 
cystomanamide biosynthesis. This specifically refers to the branched-chain fatty acid 
starter unit, an aminotransferase domain at the interphase of the PKS and NRPS modules, 
an unusual FkbH-like domain that incorporates glyceric acid in an NRPS-like manner and 
tailoring reactions involving the hydroxylation and glycosylation of the compounds.  
4.3.1.1 Starter module 
Biosynthesis starts with incorporation of a fatty acid as starter unit as pointed out by the 
identification of an acyl-CoA ligase and an acyl carrier protein. Initial feeding 
experiments showed the incorporation of labeled leucine indicating a branched chain 
carboxylic acid as starter unit.44 Based on the cystomanamide structures, the incorporated 
fatty acid is 9-methyl octanoic acid. The nature of the incorporated fatty acid could not be 
predicted by anti-SMASH 2.0 resulting in the first deviation between the predicted 
structure and the real one.  
4.3.1.2 Aminotransferase (AMT) domain 
The subsequent PKS elongation step is succeeded by an unusual reductive amination step 
conducted by an amino transferase at the interphase of the PKS and NRPS units. The 
-ketothioester, emerged from the elongation with one acetate-derived C2-unit by the 
PKS module consisting of the domains KS-AT-ACP, is transformed into the -amino 
thioester before the next elongation step by the first NRPS module incorporating D-
asparagine into the growing chain. Such an amino transferase domain was investigated 
by Aron et al.45 for the biosynthesis of mycosubtilin in a detailed study of the pyridoxal 5′-
phosphate (PLP)-dependent enzyme operating in cis within the PKS and NRPS 
biosynthetic paradigm. It was found that the amine transfer happens in two steps: First, 
the amine is transferred from an amino acid (with glutamine as preferred amino source) 
to the protein-bound PLP where pyridoxamine 5’-phosphate (PMP) is formed. The second 
step involved the transfer of the amine from PMP to the protein bound -ketothioester to 
generate the -aminothioester under regeneration of PLP (Figure 4.4). 
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Figure 4.4. Mechanism of PLP mediated amine transfer as hypothesized for the amino transferase 
(AMT) domain located on CtmA based on the results for the AMT domain of mycosubtilin 
biosynthesis (Figure modified from Aron et al.45) 
4.3.1.3 FkbH-like domain 
AntiSMASH prediction of the biosynthetic gene cluster identified a condensation domain 
as well as a peptidyl carrier protein between modules 4 and 6 located on CtmD, but was 
not able to assign them to a module or elongation step since no adenylation domain was 
identified. BLAST analysis revealed a region of the protein to be similar to proteins like 
FkbH46 and OzmB47 that are involved into the formation of glyceryl-ACP. Based on these 
results, this region or domain most likely acts in two steps (Figure 4.5): First D-1,3-
bisphosphoglycerate from the glycolytic pool is bound and the phosphate group is 
removed to receive the D-3-glyceryl-S-CtmD species (acting as a phosphatase), and 
subsequently it acts as glyceryl transferase and transfers the glyceryl group to the 
following peptidyl carrier protein (PCP). For OzmB, glycerate was assigned to be 
covalently attached to the side chain of a cysteine residue as a thioester. Therefore, this 
FkbH-like domain could substitute the adenylation domain and take over the selection 
and activation of the building block. Up to now, this was only demonstrated for 
polyketide synthases as basis for the incorporation of unusual methoxymalonyl-CoA 
extender units.46–48  
 
Figure 4.5: Selection and activation of D-1,3-bisphosphoglycerate from the glycolytic pool into the 
assembly line of cystomanamide B based on the results for OzmB in oxazolomycin biosynthesis 
(figure modified from Dorrestein et al.47) 
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4.3.1.4 Further tailoring reactions 
The biosynthetic gene cluster of the cystomanamides provides only scarce information 
about the tailoring reactions that involve the hydroxylation and glycosylation of the 
compounds. CtmB is homologous to the well-studied non-heme iron hydroxylase TauD 
and contains the conserved 2-His-1-carboxylate facial triad responsible for iron 
binding49,50 as well as the conserved Arg residue that ligates -ketoglutarate.51 Its 
similarity to SyrP from Pseudomonas syringae, which is responsible for the -hydroxylation 
of an aspartyl residue in syringomycin E biosynthesis52 indicates that CtmB is most likely 
responsible for the hydroxylation of the second asparagine residue to form L-erythro-β-
OH-asparagine. No further candidate proteins are encoded in the biosynthetic gene 
cluster that come into question for the hydroxylation of the phenylalanine residue. The 
hydroxylation of cystomanamide A-C as well as the glycosylation of C and D requires 
enzymes encoded outside the aglycon cluster.  
4.3.2  Macyranone biosynthetic gene cluster 
The prediction of the macyranone biosynthetic gene cluster was decidedly more 
complicated than of the cystomanamide cluster. The macyranone cluster is far from 
following textbook logic so that a prediction based on rules and linear assembly is highly 
overstrained in such a case. Nonetheless, it was helpful in terms that it unraveled the 
specific pattern of building blocks for the three core amino acids Thr-Thr-Leu and 
therefore allowed the identification of a candidate biosynthetic gene cluster that was later 
confirmed by gene deletion. As mentioned before, the biosynthesis of the macyranones 
deviates widely from textbook logic and multiple different unusual biochemical reactions 
are involved that are partly subject to speculation. I want to elaborate on some likely 
biochemical steps. 
4.3.2.1 Alternative amide bond formation 
The cluster prediction identified three NRPS elongation modules with specificity for two 
threonine building blocks and one leucine building block as well as one PKS elongation 
module. In addition to the three complete NRPS modules, another adenylation domain 
was found that shows an uncertain specificity for histidine. However, no modules and 
domains responsible for the incorporation of the phenylalanine and the methylmalonic 
acid could be found. This gives rise to the assumption, that the assembly line starts with 
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threonine and phenylalanine and methylmalonic acid are attached in an alternative way 
so that the formation of two amide bonds remains to be explained. Amide bonds 
represent fundamental linkages for numerous natural products and are normally formed 
by the ribosome or by the condensation domain of nonribosomal peptide synthetases. 
Since none of both seems to be true for the two amide bonds in question, other 
mechanisms have to be considered. Identification of a shunt product of the macyranone 
assembly line, that contains the shortened sequence Phe-Mma-Thr, indicates that the 
assembly line starts with the bonding of these three residues. As mentioned in chapter 3, 
only one likely candidate comes into question for the connection of the phenylalanine and 
the methylmalonic acid residue via an amide bond. MynA shows similarity to a family of 
asparagine synthetases, more detailed to a subgroup of asparagin synthetase (AS) B-like 
amide synthetases. Some members of the group were proven to be responsible for amide 
bond formation in secondary metabolites. 53–55 
MynA shows the closest similarity to PdmN from the pradimicin pathway53 (41.6 % 
identity), to RubR from the rubromycin pathway (40.3 % identity) and to FdmV from the 
fredericamycin pathway55 (39.5 % identity). The enzymes were compared to the typical 
AS B from E. coli (Chapter 3, Figure S4), which belongs to the class II glutamine amido-
transferases (20.5 % identity) and converts aspartate into asparagine via a -aspartyl-AMP 
intermediate with glutamine or free ammonia (NH3) as nitrogen source.56,57 All mentioned 
enzymes contain the conserved domains present in AS B: the N-terminal glutaminase 
domain and the C-terminal amide synthetase domain.58 In principle, the glutaminase 
domain is responsible for the hydrolysis of L-glutamine to supply a free ammonia group. 
The amide synthase domain catalyzes the conversion of aspartic acid to asparagine. 
The best characterized representative of the enzymes involved in secondary metabolite 
formation is FdmV, an amide synthetase involved in the formation of the aromatic 
pentadecaketide natural product fredericamycin.55 In vitro and in vivo studies of the 
protein have proven that it catalyzed a lactam ring formation. The protein is capable of 
using L-Glu, L-Asn and free NH3 as nitrogen source. PdmN is suspected to catalyze an 
amide bond formation by using D-Ala as amino donor and therefore to attach an amino 
acid to the aromatic polyketide intermediate of pradimicin.53 No amidating function can 
be assigned to RubR since none of the known rubromycins contains an amide linkage.54 
Analyzing the alignment of the homolog enzymes and taking into account the results of 
studies concerning the three-dimensional structure of the E. coli AS B,59 some interesting 
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facts could be used to explain the function of MynA: All class II glutamine 
amidotransferases contain a conserved N-terminal cysteine residue (Cys2) that was shown 
to act as active-site nucleophile for the hydrolysis of glutamine to glutamate and 
ammonia. A site-mutation where the cysteine residue Cys2 was exchanged for an alanine 
resulted in a catalytically inactive protein.59 This residue is retained in AS B and FdmV 
but is mutated to serine in MynA, PdmN and RubR. The mutation leads to a loss of the 
glutaminase activity in the three enzymes. For MynA and PdmN, the amide synthetase 
activity seems to be retained by using other substrates as nitrogen donor (L-Phe and D-
Ala, respectively). Additionally, four further conserved residues in the N-terminal 
glutaminase domain, that were shown to form hydrogen bonds with the glutamine ligand 
in AS B, were not retained in MynA (red arrows in yellow area in Chapter 3, Figure S4). 
This suggests a varied catalytic activity of the domain. The C-terminal amide synthetase 
domain, that is responsible for the production of the aspartyl-AMP intermediate, contains 
more active-site residues that match between AS B and MynA. The residues for the direct 
AMP binding are all conserved in MynA whereas residues for the coordination of AMP 
via metal ions (most likely Mg2+) are only conserved for one metal ion instead of two. 
These results suggest that the formation of the amide bond between the methylmalonic 
acid residue and phenylalanine occur via an AMP intermediate with phenylalanine acting 
as amino donor (Figure 4.6). 
 
Figure 4.6: Activation of methylmalonate by the formation of a methylmalonyl-AMP intermediate. 
Subsequent conversion of the methylmalonyl-AMP intermediate via a nucleophilic attack by the 
phenylalanine adapted from the principle of the conversion of aspartate to asparagine by the AS B 
from E. coli59 
For the formation of the second outstanding amide bond, two likely candidates come into 
question, both being part of the first NRPS module of macyranone biosynthesis. Either the 
adenylation domain or the condensation domain found in the cluster of the module could 
catalyze the connection. Module 1 is already unusual from the point that it actually 
contains a condensation domain. In general, NRPS starter modules do not contain a 
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condensation domain since the C domain catalyzes the condensation reaction of the 
growing peptide chain bound to the upstream PCP domain and the newly activated 
amino acid bound to the downstream PCP.60 Exceptions are starter C domains that 
acylate the first amino acid with a -hydroxy-carboxylic acid.61 It is a common motif of 
lipopeptide synthetases comprising the surfactin, fengycin and lichenysin synthetases, 
that the first module is preceded by a condensation domain.62–65 These condensation 
domains could catalyze the transfer of the fatty acid to the first amino acid. Since no lipid 
chain is involved in the macyranones, the occurrence of this first condensation domain 
already indicates an unusual priming of the assembly line. Phylogenetic analysis of the 
condensation domain using the online tool NaPDoS66 revealed its highly unusual nature 
since it represents a new clade in the phylogenetic tree of condensation domains and does 
not group with other known types like LCL type, DCL type, starter, hybrid, cyclization, 
epimerization or dual function condensation domains (Chapter 3, Figure S5). Therefore, 
the condensation domain could be responsible for a new biochemical step which connects 
the Phe-Mma intermediate to the threonine residue selected by the first adenylation 
domain.  
This first adenylation domain found in the myn biosynthetic gene cluster is a stand-alone 
adenylation domain with threonine substrate specificity localized on mynB and at the 
same time, it represents the second way how the formation of this amide bond could be 
accomplished. An amide-forming stand-alone adenylation domain was identified and 
characterized for streptothricin biosynthesis. Enzymatic assays with purified protein 
strongly suggested that amide-bond formation for the oligopeptide streptothricin was 
directly catalyzed by the stand-alone A domain Orf19. Therefore, the adenylation domain 
encoded by mynB itself could also be responsible for the amide bond formation.67 Protein 
alignment between Orf19, MynB and other stand-alone adenylation domains did not 
result in an evaluable result since the identities are all in a similar range between 20 and 
28 % (24.0 % identity between Orf19 and MynB). To get further insights into the formation 
of this amide bond, studies on the protein level would be essential. 
Summing up the above results concerning the analysis of the cystomanamide and 
macyranone biosynthetic gene clusters, in silico predictions should be seen as a useful tool 
for the identification of a candidate biosynthetic gene cluster based on a known structure, 
but it cannot substitute a detailed analysis of the respective genes. 
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4.4 From Natural Products to Drugs 
The risk and disadvantage of a screening for new compounds based on chemical and 
structural features is that we might end up with compounds not exhibiting any kind of 
biological activity as it was the case for the cystomanamides. Nevertheless, the 
compounds and the understanding of their biosynthesis contribute to our understanding 
of the bacteria, their secondary metabolism and the chemical diversity produced by them. 
Further screening of the compounds might still hit a hidden target in the future.  
The macyranones show potent activity against the parasitic agents Trypanosoma brucei 
rhodesiense and Leishmania donovani and therefore they might aid in the fight against the 
African sleeping sickness and Leishmaniasis. With their low cytotoxicity against 
mammalian cell lines, the compounds are good candidates for the drug development as 
anti-parasitic agents. This selectivity is surprising in terms that the identified target, the 
20S proteasome, is present in all eukaryotic cells so that a toxic effect on mammalian and 
parasitic cells would be expected. If we are able to decipher the mechanism of their 
selectivity for the parasitic cells, this might enable the selective use of targets shared by 
parasitic and mammalian cells. Possible explanations could be a transport-related 
selectivity so that the compounds can only enter the parasitic cells or a metabolism-
related selectivity where the compounds are for example degraded by mammalian cells.68 
For the use as a drug, also stability problems of macyranone A must be overcome since it 
has a low stability in buffered aqueous systems. The stability of all epoxyketones is an 
issue and also the approved drug carfilzomib possesses a very short systemic half-life 
limiting its applicability in the cancer treatment. Since previous studies69 as well as the co-
crystal structure of 20S proteasome and macyranone A clearly showed that the 
epoxyketone residue is crucial for the binding of the compound to its target, 
improvements of the structure are largely limited to the peptidic backbone. Replacement, 
addition and deletion of amino acids as well as making the peptide structure more rigid 
to improve the molecular stability of the peptide could be possible starting points for the 
process of a further drug development. 
4.5 Final Thoughts 
The isolation of new secondary metabolites from microorganisms has changed 
dramatically in the last half century. We cannot afford the aberration that new 
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compounds with a high UV absorbance and extraordinary biological activity will 
furthermore pop up in bacterial extracts. The exploitation of new bacterial sources with a 
high phylogenetic diversity, the development of enhanced detection and isolation 
methods and the expansion of our tools for the genetic manipulation of organisms are 
good starting points to carry forward the success of natural products. We need to strike 
out in new directions to still be able to isolate novel natural products from microbial 
sources and to make our contributions to the search for new anti-infectives to fight the 
increasing resistance of microorganisms against existing drugs. This work proves that if 
we are open for new approaches, myxobacteria still provide a valuable source for new 
natural products. With two new compound classes isolated from Cystobacter fuscus, we 
are one step further to unravel the chemical space produced by these extraordinary 
bacteria.  
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